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Abstract
Cirrhosis is the 12th leading cause of death in the United States. It is well 
documented end stage liver disease drives a patient to a catabolic state thus depleting 
them of essential nutrients. Malnutrition is often unrecognized and untreated in 
outpatients. Though BMI, nutritional intake, anthropometric measurements have been 
used in clinical trials, there still remains no standard nutritional assessment.
The purpose of this dissertation was to (1) identify the incidence of malnutrition 
in patients with compensated and decompensated liver disease utilizing defined 
nutritional parameters (Subjective Global Assessment, anthropometric measurements, 
hand grip strength, and laboratory values) and (2) correlate with care (hospital visits, 
physician appointments, outcome and quality of life) secondary to viral hepatitis, 
metabolic and alcoholic liver disease.
The conceptual framework underlying this study is derived from the literature 
based on the domains of liver function, nutrition, and malnutrition. Nutrition includes the 
chemical substances in food utilized by the body for growth, maintenance, and repair: the 
intake, digestion, and assimilation and utilization of nutrients for tissue maintenance and 
energy provision.
There is no gold standard for proper nutritional assessment of patients diagnosed 
with liver disease; notably, the traditional assessment tools are invalid with end-stage
liver disease. Ascites, edema, and diuretics cause fluctuations in weight and weight 
changes. Cirrhosis of the liver drives a patient to a catabolic state, thus depriving them of 
essential nutrients. Simple and easily applied methods are needed to identify the patients 
approaching the state of malnutrition.
Study findings presented in three papers provides a major contribution in 
discriminating the nutritional parameters of different etiologies o f cirrhosis leading to 
malnutrition.
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CHAPTER 1 
The Problem and Background 
Cirrhosis of the liver is the twelfth leading cause of death in the United States 
(Heron, Hoyert, Murphy, Xu, Kochanek, & Teejada-Vera, 2009; & Kochanek, Murphy, 
Anderson, & Scott, 2004). The cirrhotic liver is characterized by fibrosis and the normal 
architecture is converted to structurally abnormal nodules that lack lobular organization. 
It involves the entire liver and is irreversible at its late stages. Cirrhosis is a disease of 
contrasts in etiology and symptomatology. The most common etiology has been 
alcoholic liver disease and chronic viral hepatitis (Hepatitis C and Hepatitis B).
However, fatty liver disease has increasing in prevalence across the world and is known 
to progress to cirrhosis and is becoming one of the leading causes of cirrhosis globally. 
Cirrhosis can be asymptomatic or presents with manifestions of hepatic decompensation 




Nutrition is one of the most important factors that can influence overall mortality 
and morbidity. There are a variety of issues that make it difficult for patients with 
cirrhosis of the liver to maintain adequate nutritional intakes. At one end of the 
spectrum, there is severe nutritional deficiencies related to chronic alcoholic liver disease 
and viral hepatitis which has progressed to cirrhosis. At the other end of the spectrum is 
nutritional excess related to nonalcoholic steatosis (NASH) or progressive fatty liver 
disease (NAFLD). Both ends of the spectrum require specially designed nutritional 
plans.
Severe protein caloric malnutrition (PCM) is common in patients with liver 
cirrhosis, particularly alcoholics. It seriously undermines the liver’s capacity for 
regeneration and functional restoration. Studies have shown the more severe the 
malnutrition, the worse the prognosis. Nutritional supplements on an inpatient basis have 
been shown to improve nutritional status, as well as the liver function for these patients. 
The prevalence of malnutrition is as high as 80% depending on the cirrhotic population 
studied (Campillo, Richardat, Scherman, & Bories, 2003; Matos, Porayko, Francisco- 
Ziller, & DiCecco, 2002).
There is no gold standard for proper nutritional assessment of patients diagnosed 
with liver disease. Indeed, liver disease also complicates the nutritional assessment 
(McCullough, 2000). Notably, the traditional assessment tools are invalid with end-stage 
liver disease. Ascites, edema, and diuretics cause fluctuations in weight and weight 
changes. It has been well documented cirrhosis of the liver drives a patient to a catabolic 
state, thus depriving them of essential nutrients. Simple and easily applied methods are 
needed to identify the patients approaching the state of malnutrition. This study is
designed to provide a major contribution in discriminating the nutritional parameters of 
different etiologies of cirrhosis leading to malnutrition.
Background
The liver is the largest metabolic organ in the human body and integrates 
carbohydrate, fat, and protein metabolism. The liver stores vitamins and activates others. 
It detoxifies and excretes endogenous and exogenous waste products.
The majority of the cells found in the liver are hepatocytes. These hepatocytes 
are vital in maintaining homeostasis. The functions of the hepatocytes include the 
synthesis of most essential serum protein including albumin, coagulation factors, carrier 
proteins, hormonal and growth factors, the regulation of nutrients (glucose, glycogen, 
lipids, and cholesterol amino acids), the production of bile and its carriers of bile acids, 
lecithin, and phosolipids, and the metabolism and conjugation o f bilirubin, anions, 
cations, and drugs. Therefore, cirrhosis, a chronic liver disease characterized by 
replacing normal liver tissue with fibrosis, scar tissue and regenerative nodules leading to 
the loss of liver function, has major nutritional implications.
Cirrhosis represents the final stage of many chronic liver diseases. It has been 
associated with hyponutrition despite the etiology. Malnutrition is an important 
prognostic factor in liver cirrhosis (Campillo,Richardet, & Bories, 2006). There are three 
common influences which contribute to hyponutrition in the patient with chronic liver 
disease. These are: 1) a decrease of limit of intake; 2) impairment of nutrient digestion 
and/or absorption; and 3) the interference of nutrient metabolism. The relevant causes of 
dietary insufficiency are anorexia, nausea, vomiting, food tastes non palatable due to
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protein and salt restriction, early satiety, and reflux disease due to ascites and abnormal 
gut motility. Pancreatic insufficiency, cholestasis related to fat soluble vitamins, and 
drug related diarrhea from ingestion of lactulose, antibiotics, and diuretics are some of 
the causes of malabsorption. Metabolic disturbances due to infections, hemorrhages, 
protein catabolism, impaired glucose homeostasis, proinflammatory cytokines of 
interleukins, leptins and TNF alpha, and increased lipolysis and enhanced lipid oxidation 
contribute to interference of nutrient metabolism(Lee & Nieman 2007; Stratton, Green, & 
Elia, 2008).
Protein malnutrition is documented in nearly every etiology associated with 
cirrhosis of the liver(McCullough & Buglanesi, 1997). As liver insufficiency increases, 
the prevalence of protein malnutrition increases. Protein needs increase during treatment 
of malnutrition but in end-stage liver disease, the tolerance is decreased. Low levels of 
vitamins A, zinc, and magnesium have been associated with protein calorie malnutrition. 
The literature reflects protein calorie malnutrition as a common finding in patients 
hospitalized with chronic liver disease; investigations with individuals in an outpatient 
clinic are sparse.
The purpose of this study is to identify the incidence o f malnutrition in patients 
with compensated and decompensated liver disease utilizing defined nutritional 
parameters (Subjective global assessment, anthropometric measurements, hand grip 
strength, and lab values) and correlate to care (hospital visits, ER visits, physician 
appointments , outcome, and quality o f life). The degree of malnutrition will be 
compared in patients with end stage liver disease secondary to viral hepatitis, metabolic 
(NASH), and alcoholic liver disease.
5
Nutritional Assessment
The Joint Commission on Accreditation of Health Care Organizations (JACHO) 
requires a nutritional screening after hospital admission, but there are no universally 
recognized or validated standards. The areas routinely assessed are height, weight, 
weight change, dietary prescriptions, appetite, presence of chewing and swallowing, and 
major food intolerances. In the outpatient setting, dietary assessment should be done to 
determine whether the patient’s diet contributes to an increase health risk or existing 
chronic disease related problems.
Nutritional assessment is an integral part of patient assessment as it directly 
influences clinical outcomes and mortality rates. Malnutrition increases the risk of 
infections, health care costs, and decrease quality of life, prolongs hospitalizations, 
recovery after surgery, and life expectancy (Robinson, Goldstein, & Levine, 1987; 
Sherlock & Dooley, 2005).
The assessment of the nutritional status is very inaccurate in patients with chronic 
liver disease. The traditional measures used to estimate nutritional status have 
limitations. Body weight and body mass index (BMI) are insensitive in cirrhotics 
because of salt and water retention causing abdominal ascites. Abnormalities of 
lymphocyte and decrease plasma protein resulting from ascites, edema, anasarca, and 
malnutrition also contribute to the retaining of fluid. Malnutrition is an important 
prognostic factor which can influence the clinical outcome of patients with end stage 
liver disease (Campillo et al., 2006; Kondrup 2006).
In summary, end stage liver disease is a significant, chronic health problem.
There is much known about the nutritional intake during inpatient stays, in contrast less is 
known about the nutritional aspects that influence the care on an outpatient basis.
Purpose and Aims
The purpose of this descriptive correlation design study is to examine the 
relationship between nutritional assessment parameters and care among a sample of 
outpatient of adult patients with End stage liver disease (ESLD). Specifically, the aims of 
this study are.
Aim 1:
To identify the incidence of malnutrition in compensated and decompensated liver 
disease patients with end stage liver disease utilizing assessment parameters 
(SGA, anthropometric measurements, hand grip and laboratory values) among a 
sample of adult outpatients with end stage liver disease.
Aim 2
Examine the degree of malnutrition in patients with different etiologies of end 
stage liver disease (viral hepatitis, metabolic (NASH), and alcoholic liver 
disease).
Aim 3
Describe the relationships between malnutrition, hospital visits, ED visits, 
physician appointments, outcome, and quality of life among a sample of adult 
outpatients with end stage liver disease.
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Aim 3’
Describe the relationship of the intensity of care management on education and 
support lifestyle changes to improve metabolic parameters in patients with fatty 
liver disease.
Conceptual Framework 
The conceptual framework underlying this study is derived from the literature 
based on the domains of liver function, nutrition, and malnutrition. (Figure 1). Nutrition 
influences both the physical and psychological well being in a person. There is a 
growing awareness one’s nutritional status may impact the quality of life. Good nutrition 
is essential for adequate function and survival, but eating also satisfies other needs i.e.s 
eating, satisfaction, socialization, and structure to a day (McKenna and Thorig, 1995). 
Nutrition includes the chemical substances in food utilized by the body for growth, 
maintenance, and repair. It includes the intake, digestion, and assimilation and utilization 
of nutrients for tissue maintenance and the provision of energy.
Specific dietary components may have an influence on the risk of depression, 
cognitive impairment, and cognitive decline (Rogers, 2001). Subclinical deficiencies of 
antioxidants ( vitamin C,E, beta carotene, vitamin B 12, B6, and folate) and nutrition 
related disorders ( hypercholesterolanemia, hyper triglycerideanemia, hypertension, 
diabetes) have been identified as potential nutritional related risk factors (Calvanesi & 
Bryan, 2001).
The liver plays a key role in supplying nutrition to the body. It delivers the 
elements needed by the different body tissues in simple, utilizable nutrients such as
glucose, amino acids, fatty liver, and vitamins. Though the daily amounts of food 
consumed by people vary enormously, the nutrient requirements are relatively constant.
Knowledge of liver physiology is essential to understand the mechanisms at work 
in end stage liver disease. The liver provides the body’s homeostasis. It is through the 
liver; the blood sugar, cholesterol, and blood urea are maintained. The liver regulates 
most of the metabolism on the body. It is in charge of transforming foreign substances 
such as toxins in the intestinal flora and the pollutants brought in with food. It does this 
through multiple enzymes, which are controlled by numerous hormones.
The liver requires a greater metabolic potential than any other organ of the body. 
It is capable of deriving its own energy through the degradation o f  carbohydrates and 
lipids through its enzymes. It must also turn amino acids into proteins. It has specific 
functions in the digestion of the food we eat. Bile is produced in the liver and is the main 
means to eliminating cholesterol, and important for the digestion of fatty food. It 
receives a variety of sugars in the diet and converts then into a single circulating sugar, 
glucose. The liver transforms endogenous metabolites into soluble compounds easily 
excreted by the kidneys. The liver detoxifies substances foreign to the body-each 
requiring different mechanisms for this detoxification. The liver purifies the blood of 
circulating particles.
Malnutrition implies deviations from normal nutrition in which a deficiency or 
excess of energy, protein, and other nutrients cause measureable adverse effects on the 
body and function of the tissues (Elia et al., 2000). It has been divided into primary and 
secondary malnutrition. Primary malnutrition arises in the absence of disease such as
lack of food due to poverty or social isolation. Secondary malnutrition occurs in a 
relationship to a disease. In the absence of disease, the rate and magnitude of weight loss 
affect body function. In the presence of disease, nutritional support affects the function 
of tissues and cells.
In the presence of disease, nutritional support appears to produce clinical benefits. 
Nutritional support affects the function of tissues and cells. Recognition of dietary 
deficiencies and provision of both nutritional support and dietary education are needed to 
support the patient in achieving fluid and electrolyte balance, decrease frequent 
hospitalizations, and maintain adequate nutritional stores.
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Significance
Malnutrition is often unrecognized and untreated in outpatients. Due to the 
extensive role the liver plays in metabolism and maintenance of homeostasis, liver 
disorders predispose the patient to malnutrition. Alarmingly, malnutrition evolves prior 
to the clinical signs of hepatic insufficiency.
The goals of nutrition are to replenish malnourished individuals, maintain adequate 
muscle and energy reserves, and manage the patient’s symptoms to maximize the quality 
of life. To assess the overall potential effects of intervention, it is first necessary to assess 
the frequency of malnutrition and its consequences. With the standard parameters of 
nutritional assessment often invalid in End Stage Liver disease, it becomes difficult to 
identify and assess nutritional states. Although there is strong scientific evidence to 
support aggressive treatment of nutritional deficiencies in cirrhosis, few studies have 
assessed changes in nutritional status prospectively over the course of liver disease.
This study will add to the empirical base regarding nutritional assessment 
strategies to improve the nursing care for patients treated for liver disease disorders. This 
knowledge will facilitate the development of evidence based interventions to improve 




Cirrhosis of the liver is a complex pathophysiological process representing the 
final stage of many chronic liver diseases. It results in significant morbidity and eventual 
mortality in many patients and has been associated with hyponutrition despite the 
etiology. The prevalence of malnutrition is estimated to be between 65-100% in patients 
with cirrhosis (Campillo et al., 2003.) The degree of malnutrition is an important 
prognostic factor in liver cirrhosis (Campillo et al., 2006). Accurate longitudinal data on 
dietary intake patterns, physical activity, and quality o f life would be helpful to the 
understanding of how these factors may impact on health and functional status.
Malnutrition of the patient with liver disease increases the risk of infections, 
health care costs and decrease quality of life and life expectancy (Dan, Kallman. 
Srivastava, Younossai, Kim, & Younossi, 2008). Nutritional assessment of patients with 
liver disease is critical as it determines interventions that affect clinical outcomes and 
quality of life. Numerous studies have furthered our understanding of the role of
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nutritional status in the hospitalized surgical patient (Figueirdo et al., 2006). However 
the type of nutrition assessment used with the surgical patient underestimates the 
prevalence and severity of malnutrition with cirrhosis.
The literature reflects protein-energy malnutrition (PEM) as a common finding in 
patients hospitalized with chronic liver disease (Campillo et al., 2003; Matos et al., 2002). 
However there is a paucity of literature on patients treated in outpatient clinics. 
Understanding protein calorie nutrition in outpatients with liver disease is essential 
because protein needs and tolerance change for these patients as it does for hospitalized 
patients who are treated for malnutrition. In end stage liver disease, the tolerance for 
protein is decreased. Protein calorie malnutrition is also associated with low levels of 
vitamins A, zinc, and magnesium.
The causes of malnutrition in liver disease are complex and multifactoral. There are 
three common influences which contribute to hyponutrition in the patient with chronic 
liver disease. These are: 1) a decrease of limit of intake; 2) impairment of nutrient 
digestion and/or absorption; and 3) the interference of nutrient metabolism. Inadequate 
dietary intake is attributed to many factors-loss of appetite, anorexia, nausea and 
vomiting, early satiety, taste abnormalities, reflux disease and impaired expansion of the 
stomach capacity ( Aqel, Scolapio, Dickson, Burton, & Bouras, 2005; Plauth & Shutz, 
2002; Sobhonslidsuk, Roongpsiuthipong, Nahtir, Kulapongse, Songchitsomboon, 
Sumalnop, & Bussagom, 2001).
Inadequate dietary intake is associated with anorexia, nausea, encephalopathy, 
and gastritis. Frequently there is restriction of Na and protein due to ascites and edema 
decreasing the palatability of the food. Reflux disease is associated with increased ascites
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causing nausea. Impaired digestion and absorption is a contributing factor to 
malnutrition. There is a bile salt deficiency, bacterial growth, and altered intestinal 
motility associated with the antibiotics, lactulose, diuretics, and cholestrigramine given 
the patient to improve liver function and decrease encephalopathy. Portal hypertension 
changes the intestine, creates mucosal injury, and increases intestinal permeability.
Cirrhosis represents an altered state of starvation. There is hypermetabolism 
during complications of infections, hemorrhage, ascites and decompensation. An overall 
protein loss results from a reduced synthesis of urea and hepatic proteins, decrease 
intestinal protein absorption, increased urinary nitrogen excretion, and a lowered ratio of 
branched-chain to aromatic amino acids. The protein catabolism causes inflammation 
and impaired liver synthesis. Impaired glucose homeostasis is a result of hepatic insulin 
resistance and altered glucogenesis, low glycogen stores, and impaired glycogenesis. 
Classification of Cirrhosis
The Child Pugh score was based on the Child Turcotte classification (Pugh, 
Murray Lyon, Dawson, Pietron, & Williams, 1973) and has been widely used as an index 
of disease severity e.g. Grade A (mild) to Grade C (severe),for patients with end stage 
liver disease.. There are five factors included in the Child Pugh classification, 2 clinical 
factors: ascites, hepatic encephalopathy, and 3 laboratory factors: levels of bilirubin, 
albumin, and prothrombin time. The grading system indicates the degree of hepatic 
reserve and function. The major criticism of this scoring system is the subjectiveness 
involved in evaluation ascites and hepatic encephalopathy. This can cause and does 
cause differences in patients with very similar laboratory markers. However, it remains 
the most common and feasible method to categorize cirrhotic patients.
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major food intolerances. In the outpatient setting, dietary assessment should also be done 
to determine whether the patient’s diet contributes to an increase health risk or existing 
chronic disease related problems.
Despite liver disease being the primary cause of malnutrition, it is often 
unrecognized and is untreated particularly in outpatients. Further insults to the liver at 
this stage, can lead to decompensation, fluid retention (ascites) and encephalopathy. 
Clinical detection of malnutrition usually occurs in the advanced stages of deficiencies of 
nutrients. Biochemical or other tests can identify the deficiency before the specific 
clinical manifestations become apparent. Detection of subclinical malnutrition has the 
obvious advantage that a condition can be identified and treated at an early stage to 
improve or prevent progression of the condition.
Malnutrition is an important prognostic factor which can influence the clinical 
outcome of patients with end stage liver disease (Campillo, Richard et al., 2006;
Kondrup, 2006). Anthropedric tools-MAMC, hand grip strength are known to be 
predictors of malnutrition in adults with cirrhosis. The use of skin fold anthropometric 
measurements have been shown to correlate most reliably with malnutrition in liver 
patients but not with the severity of liver disease. Albertino, Gatta, Amobdio, Merkel, 
DiPascoli, Bofo, & Caregaro (2001) included mid-arm muscle circumference (MAMC) 
and triceps skinfold thickness (TST) metrics and found improved prognostic accuracy of 
the Child Pugh score. Abbott, Thomson, Steadman, Gatton, Bothwell, Kerlin, Wall & 
Lynch (2001) found advanced Child Pugh scores were associated with diminished muscle 
status. Malnutrition occurs in all clinical stages, but it becomes more severe related to
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the degree of liver injury. Malnourished patients have an increased prevalence in 
morbidity and mortality (Gunsar et al., 2006).
The assessment of the nutritional status is very inaccurate in patients with chronic 
liver disease. The traditional measures used to estimate nutritional status have 
limitations. Body weight and body mass index (BMI) are insensitive because of salt and 
water retention. Abnormalities of lymphocyte and decrease plasma protein also 
contribute to the retaining of fluid. Bioelectrical impedance analysis (BIA) is hampered 
by body water retention. Nonetheless, The European Society for Clinical Nutrition and 
Metabolism identify the Subjective Global Assessment (SGA) and anthropometric 
parameters as reliable in assessing the nutritional state of cirrhotic patients (Figueiredo, 
De Mello Perez, & Kondo, 2005)
The required amounts o f essential nutrients differ by age and physiologic state. 
Energy intake must match energy output to maintain one’s weight. Restoring energy 
expenditure (REE) and physical activity are the major components o f energy output. 
Illness alters the ability of the body to engage in physical activity and its REE.
Sodium concentrations have been recognized as an important prognostic factor in 
liver cirrhosis. Hepatorenal syndrome, ascites, and death from liver disease are 
associated with hyponatremia ( Arroyo &Colmenero 2003; Borroni, Maggi, Sangiovanni, 
Cazzaniga, & Salerno, 2000). Kim, Flamm, Di Bisseglie, and Bodenheimer (2008) 
added sodium concentration with the MELD score and found it to be significantly 
associated with mortality.
The literature reflects protein calorie nutrition is a common finding in patients 
hospitalized with chronic liver disease. However, investigations o f individuals in an 
outpatient clinic are rare. Most patients are also non patients with chronic alcohol abuse. 
Protein calorie malnutrition is frequently found in patients with end-stage liver disease. 
Protein needs increase during treatment o f malnutrition but in end-stage liver disease, the 
tolerance is decreased. Low levels of vitamins A, zinc, and magnesium have been 
associated with protein calorie malnutrition.
Fat soluble vitamins (A, D, E, and K) are closely associated with lipids. They can be 
stored and their functions are generally related to structural activities. Vitamin A. There 
are two dietary forms of vitamin A-retinol and carotene. Retinol is found only in animal 
foods and its compounds are deposited primarily in the liver. Carotene is found both in 
animal sources as well as in plants. It is converted to vitamin A in the liver. Vitamin A 
and carotene are absorbed through the intestinal mucosa, entering the blood stream via 
the lymphatic system and carried to the liver for storage and distribution to the cells. 
Vitamin A plays a role in iron utilization, humoral immunity, vision adaptation to light 
and dark, t-cell mediated immunity, natural killer cell activity, and phagocytosis.
Vitamin A decreases with cirrhosis and protein energy malnutrition; It increases with 
hepatosplenomegaly, hypercholesterolemia, and hyperlipidemia.
Vitamin D. There are two compounds with Vitamin D activity-ergocalciferol and 
cholecalciferol. Vitamin D is involved in the regulation of calcium and phosphorus. It 
also works with other vitamins- A, C, and K, hormones, and minerals-calcium, 
phosphorus, and magnesium to affect bone growth. It is found naturally in fish, liver and
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oils; it is fortified in dairy products. In liver disease, the concurrent use of thiazide and 
diuretics can lead to hypercalcemia.
Vitamin E. Vitamin E, also known as tocopherol, is a generic name for a group 
of compounds with similar physiological activity. It oxidizes very slowly giving it an 
important role as an antioxidant. It neutralizes free cell radicals and provides a protective 
role in preventing oxidation of the unsaturated fats. Vitamin E works with a selenium- 
containing enzyme to provide another mechanism of protection for the cell membrane of 
fatty acids for the oxidative damage. Vitamin E decreases with malabsorption syndromes 
with steatorrhea and in protein energy malnutrition.
Vitamin K. Vitamin K is synthesized by intestinal bacteria and can be found in 
plants. It requires bile salts and pancreatic secretions for absorption. As with vitamin A  
it is transported via the lymphatic system to the liver for storage. The major function of 
vitamin K is to catalyze synthesis of blood clotting factors by the liver. It is essential for 
maintaining normal levels of four blood clotting factors-prothrombin (factor II), serum 
prothrombin conversion accelerator (Factor IH), plasma thromboplastin component 
(factor IX), and Stuart-Prower factor (Factor X). Vitamin K activates each of these 
protein synthesized by the liver. Decreases in vitamin K are seen in patients with liver 
disease and high phosphates.
Water soluble vitamins cannot be stored, though they are generally distributed 
through the body tissue maintaining a tissue saturation level. They are easily absorbed 
and transported to the cells and their function is related to cell metabolism and structure. 
These are B complex and Vitamin C.
2 0
Vitamin C. Vitamin C is also an antioxidant along with Vitamins A and E. 
Vitamin C is required to build and maintain body tissues-bone matrix, cartilage, dentin, 
collagen, and connective tissues. It promotes non-heme iron absorption, carnitine 
biosynthesis, and conversion of dopamine to norepinephrine. A decrease in vitamin C is 
seen in alcohol abuse, inflammatory disease, and oxidative damage.
Biotin is a micronutrient involved in glucogenesis. It is a coenzyme in 
metabolism that functions on the tricarboxyloc cycle for release o f  energy. Protein- 
energy malnutrition can lead to a deficiency in biotin. Clinical signs of biotin deficiency 
include nausea and depression.
Vitamin B12-cobalmin deficiency is associated with deficiencies in vitamin B6 
and folate. It is a coenzyme in the synthesis of hemoglobin, RBC’s, and DNA. Folic 
acid is used in the synthesis of DNA and helps convert vitamin B 12 to a coenzyme form 
in the body. It is needed for growth and development of RBC’s, and helps to lower 
homocysteine levels in the body by breaking down amino acids. It goes through the 
enterohepatic circulation to be regulated.
Vitamin B6 pyridoxine is a coenzyme in amino acid, lipid, and protein 
metabolism, erythrocyte function, modulation of hormones, nervous system function, and 
direct conversion of tryptophan to niacin or to serotonin. Vitamin B2 riboflavin is a 
coenzyme in protein and energy metabolism and conversion of other vitamins into active 
forms. The thyroid adrenal hormone controls the conversion to the coenzyme forms. 
Vitamin B 1, thiamin, is a coenzyme in carbohydrate metabolism. A decrease in 
thiamine may elicit Wemicke-Korsakoff syndrome and Beri-Beri cardiomyopathy.
Nutritional Assessment Measures
There have been a variety of comprehensive assessment tools utilized in an attempt to 
identify patients at risk of or with malnutrition, yet the literature reflects conflicting 
information on the patient with End Stage Liver Disease. There is no gold standard for 
proper nutritional assessment of patients diagnosed with liver disease since liver disease 
also complicates the nutritional assessment (McCullough, 2000). The traditional 
assessment tools are invalid with end-stage liver disease. Ascites, edema, and diuretics 
cause fluctuations in weight and weight changes. Bioelectrical impedance and dual x-ray 
absorptiometry are altered by fluid retention (Figueiredo et al., 2005; Figueiredo et al., 
2006). The search continues for the ideal nutrition marker. Early identification of the 
malnourished cirrhotic patient, regardless of etiology, is essential to develop effective 
interventions. The nutritional goals include providing adequate calories, protein, and 
nutrients to support hepatocyte regeneration within the existing metabolic alterations of 
liver disease.
Malnutrition can lead to further morbidity with increase rates of septic 
complications, poorer quality o f life, reduced life span. The liver plays a key role in the 
carbohydrate, lipid and nitrogen metabolism within of our bodies. Therefore, cirrhosis 
has major nutritional implications. Severe protein caloric malnutrition (PCM) is common 
in patients with liver cirrhosis. It seriously undermines the liver’s capacity for 
regeneration and functional restoration. Studies have shown the more severe the 
malnutrition, the worse the prognosis. Nutritional supplements on an inpatient basis have 
been shown to improve nutritional status as well as the liver function for these patients. 
Prevalence is as high as 80% depending of the cirrhotic population studied (Campillo et
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al., 2002; Matos et al., 2002). Malnutrition affects lean body mass wasting. Decreases in 
vitamins, metals, and plasma protein may occur before lean body mass wasting (Matos et 
al., 2002; McCullough & Falck-Ytter, 1999).
Nutrition was used as a prognostic indicator of the Child Turcotte classification for 
estimating mortality in patients having portocaval shunt surgery (Child & Turcotte,
1964). It has been shown nutrition in alcohol liver disease, decreased infections, 
enhanced wound healing, and decreased the need for hospitalizations (Hirsch, Bunout, de 
la Maza, Iturriaga, Petermaim, Icazar, & Gattas, 1993).
European Society for Clinical Nutrition and Metabolism argue simple bedside 
methods for SGA and anthropometric parameters are reliable in assessing nutritional state 
of cirrhotic patients.
However, the obstacles continue in the evaluation of nutritional status in patients with 
cirrhosis. Weight is affected in the presence of ascites and edema. Though the patient 
may increase weight, lean body mass might be reduced. Albumin and pre-albumin are 
related to low levels of synthesis rather than poor nutritional status, though nutrition does 
play a role. Indeed, anthropometric measurements may be unreliable due to third 
spacing. This may result in an over-estimation of these values. Additionally, there may 
be potential problems associated with poor inter-observer reproducibility. Hand grip 
strength and respiratory muscle strength may be more useful when taken serially. The 
SGA has an inter-observer reproducibility rate of 80%. See Table 1 for Studies which 
Identified level of malnutrition.
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The purpose of this study was to examine the incidence o f malnutrition in patients 
with end stage liver disease utilizing defined nutritional parameters (subjective global 
assessment, anthropometric measurements, hand grip strength, and lab values) and 
correlate to care (hospital visits, ER visits, physician appointments , outcome, and quality 
of life). In this chapter a description of the design, sample, data collection, and analytic 
techniques will be presented. The protection of human subjects and study limitations 
will also be addressed.
Specific aims:
A i m  1:
To identify the incidence of malnutrition in compensated and decompensated liver 
disease patients with end stage liver disease utilizing assessment parameters 
(SGA, anthropometric measurements, hand grip and laboratory values) among a 
sample of adult outpatients with end stage liver disease.
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Aim 2
Examine the degree of malnutrition in patients with end stage liver disease 
secondary to viral hepatitis, metabolic (NASH), and alcoholic liver disease.
Aim 3
Describe the relationships between hospital visits, ED visits, physician 
appointments, outcome, and quality of life among a sample of adult outpatients 
with end stage liver disease.
Aim 3’
Describe the relationship of the intensity of care management by the Advanced 
Practice Registered Nurse on education and support of lifestyle changes to 
improve metabolic parameters in patients with fatty liver disease.
Design
A descriptive, repeated measures, correlational design was used to examine the 
relationship between nutritional assessment parameters and care while an outpatient of 
adult patients (>18 years) with end stage liver disease (ESLD).
Sample and Sampling
A purposive sample o f 50 outpatients with end stage liver disease, secondary by 
histology or clinical picture to viral hepatitis, metabolic (NASH), and alcoholic liver 
disease were recruited from a community based hepatology clinic located in Southern 
California. There are two locations of this clinic-Coronado and San Clemente. These 
clinics provide specialized care to address the needs of individuals with liver disease in
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an effort to manage their liver condition and improve quality of life and survival. The 
advantage of this sampling is the clinic is a regional site for patients with cirrhosis of the 
liver. They have over 200 referrals per year to this clinic. End stage liver disease was 
defined as an irreversible condition that occurs with progressive liver damage. It leads to 
imminent complete failure of the liver and death.
Inclusion criteria:
Subjects met all of the following inclusion criteria to be eligible for participation in this 
study:
1. Willing and able to provide written informed consent.
2. Male or female, age eighteen or greater
3. Confirmation of cirrhosis documented by either
a. Liver biopsy
b. Clinical exam, or
c. Non-invasive alternative to liver biopsy such as fibro-test, fibro-scan, or 
acoustic radiation force impulse imaging.
4. Subject has not been treated with any investigative drug or device within 30 days 
of the screening visit.
5. A female subject is eligible to enter if she is not pregnant or nursing
6. Subject must be in generally good health as determined by investigator.
Exclusion criteria:
1. History of solid organ transplantation
2. Chronic liver disease of hemochromatosis or Wilson’s disease
3. Current history of clinical hepatic compensation (e.g. jaundice, severe ascites, 
encephalopathy or variceal hemorrhage
4. Excessive alcohol ingestion defined as >3 glasses per day (1 glass is equivalent to 
beer [284 ml], wine [125 ml] or distilled spirits [25 ml] for females and >4 glasses 
for males.
5. Patients with hepatocelllular carcinoma or invasive malignancy
6. Malabsorption short bowel syndrome
7. Parental nutrition within the last 3 months,
8. Patient with a comorbidity of AIDS
9. Patients on renal dialysis or renal failure
10. Rehabilitating infections i.e. Tuberculosis, chronic fungal infections
11. Rehabilitating chronic conditions i.e.
12. Severe pulmonary disease (02 dependent or FEV <50% predicted value)
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13. History of significant cardiac disease (congestive heart failure, myocardial 
infarction within last 2 years)
14. Pregnant or nursing female




The independent variable-malnutrition- was measured using the subjective global 
assessment. It is a general nutritional assessment based on current weight, height, 
nutritional history, changes on physical examination and existing medical conditions.
The patients were classified as being well nourished or having mild, moderate, or severe 
malnutrition. High specificity (96%) has been reported in the detection of malnutrition in 
liver patients (Detsky, McLaughlin, & Baker, 1987; Jeejeebhoy, Detsky, & Baker, 1990). 
Though originally used to categorize surgical patients, this nutritional classification has 
been shown to be a reliable nutritional assessment tool for renal dialysis and liver failure 
patients (Hasse, Strong, Gorman, & Liepa, 1993). A single clinician collected this data.
Quality of Life
The Chronic Liver Disease Questionnaire is a disease specific instrument. It is 
designed to assess the health related quality of life in patients with chronic liver disease. 
It is a multidimensional construct which includes the psychosocial, social, functional 
aspects, and physical aspects of chronic liver disease. It was developed by Younossi, 
Guyatt, Kiwi, & King (1999) for patients with chronic liver disease of all etiologies and
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stages of cirrhosis. It produces a summary score and correlates with the severity of liver 
disease. There is construct validity.
The etiology of the cirrhosis was determined by history and routine tests for 
Hepatitis. The diagnosis for cirrhosis was determined by history, clinical or liver biopsy 
and laboratory data.
Dual Energy E-Ray Absorptiometry
The DEXA scan is used to measure relative visceral and subcutaneous fat 
distribution and bone density. The persons who perform X-Ray Bone Densitometry in 
California are required to possess a certificate as a California Diagnostic Radiologic 
Technologist, California Radiography Supervisor and Operator permit, or an X-Ray 
Technician Limited permit in the X-Ray Bone Densitometry Category.
Laboratory Specimens for Blood Work
The Joint Commission has standards which need to be met for a laboratory to 
obtain accreditation. The laboratory is required to meet national health and safety 
standards. Trained and certified technicians and laboratory scientists manage, study, and 
analyze these blood samples. Regulatory agencies o f the government monitor the 
laboratories through proficiency testing programs for routine quality control tests for 
equipment and test methods, and validating appropriate handling of the samples 
collected.
34
Table 2: Outcome Variables
Test Outcome measures Method
Demographics, Medical 















End Stage Liver Disease 
Date of diagnosis 
Method of Diagnosis 
Symptoms of Liver Disease 
Past month 
Medical/Family history (1st 
degree)












Medications use within the 
past 6 months (including 
vitamins and supplements)











Blood work drawn at 
Laboratory per standard lab 
protocol. The lab will 
provide certification-yearly 
to meet standards for blood 












Prothrombin time (PT) 



















Dietary Intake Total daily calories 
Daily fat calories 
Saturated fat calories 
Unsaturated fat calories 
Daily protein calories 
Daily carbohydrate calories 
Daily mineral intake 
Daily vitamin intake
3 day dietary recall





Lean body mass 
Fat mass 
Bone Mass 
Tricep skinfold (TSF) 








Physical Activity and Sleep 
Patterns
Total time spent walking 
(daily)
Total time spent exercising 
(daily)
Amount of time spent 
sleeping (daily)
Self report
Quality of Life Perception of illness and 
affect on life
Quality o f Life .
Questionnaire
Chronic
Liver Chronic Disease 
Questionnaire
Protocol:
Patients identified with cirrhosis o f the liver were assessed per standard medical practice 
with a review of available medical records, thorough clinical history and physical exam.
1. All patients were seen by physician or nurse practitioner to determine eligibility 
for study. If eligibility met, patients were asked to participate in study. The study 
was explained and written consent form all subjects was obtained.
2. On initial visit demographics data was collected or reviewed if the patient was 
previously seen in the clinic-age, sex, ethnicity, alcohol use history, tobacco 
history, medical/family history of diabetes, cancer, endocrine disease, 
hypertension, CVA, hyperlipidemia, liver disease, coronary artery disease, 
bariatric disease, medications used within past 6 months including vitamins and 
supplements. IF the patient is a smoker, the number of cigarettes smoked per day 
and the length of time was also recorded.
3. All patients were evaluated at 1st visit, with 3 months, 6 months ,and 1 year 
follow-up by dietary evaluation, clinical evaluation and physical examination.
a. The dietary evaluation included a 3 day dietary intake recall using Diet 
Analysis Plus software version 7.1 to evaluate and analyze nutrient intake 
for protein, carbohydrates, fat, vitamin e, vitamin d, zinc, magnesium, 
vitamin c, vitamin a, calcium and was compared to the recommended 
dietary intake. The patient completed the diet and quantities were 
estimated by food diagrams (Nutritional Consulting Enterprises two- 
dimensional food portion visual chart) and models.
i. Sleep pattems-number of hours per night, number of times wake 
up, naps-length and number
ii. Current physical activity-mode, frequency, intensity, and duration
b. Patients had anthropometric measurements performed-weight, height, 
body mass index (looking for trends), triceps, and mid arm circumference. 
Measurement of standing height was done using a stadiometer-wall 
mounted, and standing weight using a balanced beam scale. BMI was 
calculated using weight (kg)/height (m2). The BMI classification is as 
follows: underweight ifBMI<18.5, normal weight if BMI 18.5-24.9, 
overweight if BMI is 25.0-29.9 and obese if BMI > 30 (WHO, 1998).
Skin fold. Lange Skin fold Calipers were used to measure the triceps and 
biceps, and the mid arm circumference was measured 3 three times with 
average used with a tape measure (Paper or plastic better?). Skin fold 
measurements of the biceps and triceps were measured in millimeters, 
three times, and the average was recorded at each of these sites. The 
triceps was measured at the mid-point between the acromiale (lateral edge
of the acromial process) and the radial (approximately the elbow joint, on 
the mid-line of the posterior surface of the arm. The arm was relaxed with 
the palm of the hand facing forward. The vertical pinch was parallel to the 
long axis of the arm. The biceps was measured in the same way as the 
triceps, but on the anterior surface of the arm.
Muscle strength will be measured using a dyanometer. This is a hand 
held device designed to measure muscle strength in a simple way. The 
participant was in a standing position with arms at their sides without 
touching their body. The elbow was slightly bent. The test was 
administered on the non dominant hand. The participant did squeeze the 
dynamometer with as much force as possible, being careful to squeeze it 
only once. This was done 3 times with a pause o f 10-20 seconds between 
to avoid the affects of muscle fatigue. The results were recorded to the 
nearest pound or kilogram.
Subjective Global Assessment was completed by researcher at the time 
of the visit.
i. The subjective global assessment(SGA) has been found to be 
highly predictive of nutritional assessment(Detsky et al., 1987; 
Jeejeebhoy et al., 1990). Though originally used to categorize 
surgical patients, this nutritional classification has been shown to 
be a reliable nutritional assessment tool for renal dialysis patients 
and liver failure patients(Hasseet al, 1993). It is based on four 
elements of the patient’s history (weight change, dietary intake,
gastrointestinal symptoms, and functional impairment) and three 
elements of the physical examination ( loss o f subcutaneous fat, 
muscle wasting, and presence of edema, and ascites). The 
information is scored as either A, B, or C which corresponds to 
the clinical observer’s subjective opinion o f  the patient’s 
nutritional status. The clinician examines the form to obtain a 
general feel for the patient’s status. The more B and C ratings the 
patient has, the more likely the patient is to be malnourished. After 
evaluation the patients are categorized into three distinct classes of 
nutritional status; well nourished, moderately malnourished, and 
severely malnourished.
Blood work was done after a 12 hour fast for measurements of glucose, 
insulin, triglyceride, HDL, LDL, total cholesterol, HgbAlC, albumin, 
aspartate aminotransferace (AST), alanine aminotransferase ( ALT), 
alkaline phosphatase, INR, total serum, direct bilirubin, and leptin. 
i. Insulin resistance(IR) was estimated indirectly using the 
Homeostasis Model Assessment (HOMA) as described by 
Matthews (1985). It is calculated as follows: HOMA = [fasting 
insulin (uU/ml) * fasting glucose (mmol)/22.5]. There is no 
clearing defining value for IR. Many have used HOMA-IR greater 
than or equal to 3 as the cut-off value ( Cortez-Pinto and Camilo 
2004; Marchesini, Bugianesi ,Forlani, Cerreli, Lenzi, Manini,
Natale, Vanni, Villanova, Melchionda, &Rizzetto, 2003; Machado 
& Cortez-Pinto 2005) 
e. Additional tests at initial visit and 6 months include CBC, with
differential including total lymphocytes count, BUN serum creatinine, C- 
reactive protein, ferritin homocysteine, serum and ionized calcium, TSH, 
serum zinc, selenium, thiamin, riboflavin, plasma 25-hydroxy vitamin D, 
plasma vitamin A and retinol binding protein ration.
Body Composition and Distribution
a. Body composition and distribution was determined using dual energy x- 
ray absorptiometry (DEXA). The instrument was calculated by according 
the manufacturer’s guidelines daily. Lean body mass and fat mass was 
determined from the whole body scan. The percent of fat was calculated. 
Body mass index was calculated from height and weight. A waist to hip 
fat ration will be determined between the fat tissues in the android (central 
) and gynoid (hip and thigh) software defined regions.
Classification clinical staging o f cirrhosis. There are two clinical staging methods 
for cirrhosis that are widely used. The first is Child-Turcotte-Pugh (CTP) and the 
second is Model for End-Stage Liver Disease (MELD). The CPT method utilizes 
three quantitative variable: bilirubin, albumin, and platelets or INR and 2 
qualitative variables of encephalopathy and ascites. The score ranges from 5 to 
15 and is classified as Class A with a score of less than 7, Class B with a score 
between 7 and 9 points, and Class C with a score of 10 to 15 points. (See Table 3 
Child-Turcotte-Pugh Scoring System). A patient with a score of less than 7,
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Child A is considered to have compensated cirrhosis and a score greater than 7 
(Child B and C) is considered to be uncompensated.
Table 3. The Child-Pugh Score: Grading System for Cirrhosis




Ascites (grade) Absent Mild Moderate-
Severe
Bilirubin (mg/dL) <2 2-3 >3





Table 4: Timeline for Scheduled Visits and Activities for Each Visit
screening Baseline/day
1




Vital signs XX XX XX XX XX
Height XX
Weight XX XX XX XX XX
Anthroprometrics XX XX XX XX
Subjective global 
assessment
XX XX XX XX
Hand grasp 
strength
XX XX XX XX








work based on 
condition
XX XX XX XX
DEXA XX XX
Quality of Life XX XX XX
3 day diet XX XX XX XX XX
Changes in status- 
hospitalizations, 
ED visits
XX XX XX XX XX
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Analysis
Descriptive statistics (means and standard deviations) were calculated for all 
continuous variables and frequencies and percents were generated for the non-continuous 
variables. Chi-Square was used to test for differences among groups in nominal 
categorical outcomes. Data was analyzed using the Statistical Package for the Social 
Sciences (SPSS) version 20.
Primary analysis used one-way analysis o f variance (ANOVA) with one between 
subjects factor (group: Child A, Child B, Child C) examining the differences among 
cirrhosis groups in nutritients, total body fat (%fat), and muscle strength. When 
appropriate (significant ANOVA F value), post-hoc pairwise contrasts using the Tukey 
criteria were examined to determine specifically where group differences occurred.
Human Subjects
Prior to the beginning of the study, Institutional Review Board approval was obtained 
from all the institutions involved- University o f San Diego’s Institutional Review Board 
and the Southern California Liver Center. All participants signed an informed consent 
and given a copy of the form to keep. Participants were told they could leave the study at 
any time, and that participation/non-participation did have any effect on their ability to be 
seen in the clinic. Benefits of participation would include identification of a decrease or 
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Emerging Health Conditions: Non-alcoholic Fatty Liver Disease 
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Abstract
This article summarizes the clinical features, pathophysiology, natural history and 
current treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic 
steatohepatitis (NASH). The term nonalcoholic fatty liver disease (NAFLD) describes a 
spectrum of liver diseases ranging from hepatic steatosis to steatohepatitis, fibrosis of the 
liver and cirrhosis. NAFLD is now recognized as one of the most common liver diseases 
worldwide and therefore will often be seen by Advance Practice Registered Nurses 
(APRN). Nonalcoholic fatty liver disease is correlated with visceral obesity, insulin 
resistance and Type 2 diabetes, metabolic syndrome, and lipid deposition in the
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hepatocytes in the liver parenchyma. The pattern of disease is similar to alcoholic liver 
disease in those without a history of chronic alcohol use. It is estimated that 39 to 95% 
of obese adults have NAFLD. The prevalence of hepatic steatosis varies with ethnicity. 
Hispanics have the highest prevalence of fatty liver at 45%, Whites with 33% and Blacks 
with 24%. Treatment of NAJFLD has been focused on treating the underlying metabolic 
risk factors.
If left untreated, 5-10% of those with NAFLD/NASH develop end stage liver 
disease, some of them will require transplantation albeit the large majority are not good 
candidates for liver transplantation (BMI >37). Given the shortage of available organs, it 
is imperative to identify and treat NAFLD/NASH earlier. Advanced Practice Registered 
Nurses are seeing obese clients, insulin resistant diabetics clients, and metabolic 
syndrome clients in primary care settings. We can identify NAFLD/NASH patients 
early, provide education for our clients and begin management of this progressive 
disease. We can also identify earlier those patients who will need referral to a liver 
specialty clinic for further aggressive management. Thus with early detection, we may 
be able to stop the progression of this liver disease.
Non-alcoholic fatty liver disease (NAFLD) is an alcoholic like liver disease that 
occurs in individuals who consume less than 20 grams of alcohol per day. NAFLD can 
inflict heavy burdens on health and well-being (Sandler, Everhart, Donowitz,
Adams,Cronin, Goodman, Gemmen, Shah, Advic, & Rubin, 2002). Similar to alcohol- 
induced liver disease, NAFLD encompasses liver damage, ranging from non-alcoholic 
fatty liver (NAFL) at the most clinically benign end of the spectrum to cirrhosis on the 
opposite extreme, where most liver-related morbidity and mortality occur. In NAFL, the 
liver is steatotic (fat) but generally maintaining its structure and liver function. Non­
alcoholic steatohepatitis (NASH) is more severe form than NAFL because there is 
increased hepatocyte death(steatohepatitis) in addition to steatosis. The liver injury in 
NASH triggers a repair and regeneration response that sometimes leads to progressive 
fibrosis and cirrhosis, in which the liver is distorted by regenerating nodules and broad 
fibrous bands. Persistent abnormal liver enzymes and imaging modalities, however, have 
limited sensitivity for detecting liver steatosis, steatohepatitis and cirrhosis. In addition, 
there is no single test that can distinguish NAFLD from other causes of fatty liver 
disease. Currently, NAFLD is a diagnosis of exclusion (Brunt, 2004; McCullough, 2004; 
& Neuschwander-Tetri & Caldwell, 2003).
The actual prevalence of NAFLD in the United States is unknown, in part because 
a liver biopsy is required for a precise diagnosis. Data from the National Health and 
Nutrition Examination Survey (NHANES III) suggest 24% o f American adults may have 
NAFLD, while other studies suggest that 30% of the population have NAFLD (Sandler et 
al. 2002). In 2006 liver disease ranking increased from 5th to 15th as the leading cause of 
death depending on ethnicity (Heron et al, 2009).
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Five percent of end stage liver disease has been identified as cryptogenic 
cirrhosis, a term used to classify cirrhosis of unknown origin. This is currently the third 
most common indication for liver transplantation (Schreuder, Verwer et al. 2008).
NASH can progress to cirrhosis, hepatocellular carcinoma, and liver failure (Browning, 
Szcepaniak et al, 2004; Harrison & Bisceglie, 2003; Machado, Marquea-Vidal et al,
2006, & Nomura, Kashiwagiet al, 1988). NASH is now identified as a primary cause of 
15 to 73% of cryptogenic cirrhosis. The steatosis characteristic o f NASH disappears with 
disease progression, however, making it difficult to identify NASH as the culprit.
NAFLD is emerging as the most common cause of liver disease and it is the probable 
cause when patients present with type 2 diabetes, hyperlipidemia, and obesity after 
excluding other common causes of chronic liver diseases. Other underlying etiologies 
are silent autoimmune hepatitis, unidentified viral hepatitis, occult alcohol abuse or other 
toxins, and cholestasis (Ayata, Gordon et al, 2002; Hubscher, 2009, Maheshwari & 
Thuluvath, 2006).
Studies have shown a generally low risk of progression but more rapid 
progression is associated with obesity and diabetes. The risk o f progression from 
NAFLD to cirrhosis is 1-2% over 15 to 20 years, whereas the risk for progression from 
NASH to cirrhosis is 12-20% over 8 years (Adams, Lymp et al., 2005; Adams, Sanderson 
et al., 2005; Dam-Lasent, Becker t al.,2009; & Sanyal, Banas et al.,2006).
Limited data suggest that 3% of individuals with NAFLD may have 
nonalcoholic steatohepatitis (NASH), with rates rising to 37% among the morbidly obese. 
The progression o f cirrhosis to end-stage liver disease is 39-63% in patients with NASH. 
Of these patients, 22-33% will experience liver disease-related mortality, with a survival
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time of 5-7 years. The development of ascites is the most common liver-related 
morbidity. The mortality rate is higher than in the general population (standard mortality 
ratio, 1.34; 95% CI:!.00-1>76;p  = 0.03)(Adams, Lymp et al. 2005).
Globally, it Is estimated the prevalence of fatty liver has increased from 14% in 
1988 to 31% in 2005 (Adams, Sanderson et al. 2005). For APRNs, this means 
approximately 33% of patients have fatty livers. Numerous considerations, however, 
may complicate the diagnosis. The differential diagnose one must consider are Wilson’s 
disease, autoimmune hepatitis, hepatitis C virus, galactosemia, and alcohol use/abuse. 
Additionally, high serum ferritin and transferrin levels need to be evaluated.
The presence of steatosis on histological examination of a liver biopsy is 
necessary for a diagnosis of NASH. The steatosis is most commonly macrovesicular, 
although some microvesicular steatosis may be seen. In addition, a mixed inflammatory 
infiltrate consisting of neutrophils and degeneration and hepatocyte necrosis may be 
present. Mallory’s hyaline bodies may also be seen (Harrison & Bisceglie, 2003). (See 
table 5.)
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Table 5: Histologic Spectrum of Non-Alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease (NAFLD)
Histologic Spectrum of Liver Disease
NAFL type 1-fatty liver (steatosis)
Type 2-steatosis + nonspecific inflammation
NASH Type 3-steatosis + ballooning degeneration and 
increased hepatocyte death (steatohepatitis)
Type 4-steatosis + fibrosis and/or Mallory bodies
Cirrhosis -complication of Types 3 and 4. 
Regenerative nodules + fibrosis
Multiple risk factors are associated with non-alcoholic fatty liver disease: obesity 
(high BMI or waist to hip ratio), metabolic syndrome, type 2 diabetes mellitus, alcohol 
ingestion, female gender and inflammation (including grade and C-peptide). Although 
most of the studies have been small and they used a variety of histological scoring 
systems, these are the risk factors identified in the studies (Stengel & Harrison, 2006).
It is questionable whether fatty liver is a risk factor for some of these risk factors 
or part of a disease complex. Cirrhosis has been found in patients worked up for a 
gastric bypass and in patients with cardiac failure not doing well, especially with a 
history of diabetes mellitus. NASH has also been identified in patients with a family 
history (Rubenstein, Lavine et al, 2008; Younossi, Gramlich et al., 2004).
Obesity related liver disease
Several factors have led to a state o f decreased calorie utilization over the past 50 
years. Sedentary lifestyle, energy-dense foods, and increased consumption of foods and
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drinks with high fructose have contributed to an increase in adipogensis. However, while 
obesity-related chronic inflammation plays a very strong supporting role in the 
pathogenesis of NAFL and NASH, the mechanisms that drive the progression from 
NAFL/NASH to cirrhosis remains less well understood.
It is thought to be a two hit process. The first hit is an accumulation of fat in the 
hepatocytes. Twenty percent of the glucose eaten at a meal is metabolized by the liver, 
but 100% percent of fructose eaten is metabolized by the liver. With an accumulation of 
fat in the hepatocytes, there is an increased delivery of fatty acids to the liver, inhibition 
of B-oxidation of fatty acids, decreased synthesis or secretion of very low density lipids, 
hyperlipidemia, diabetes mellitus, and obesity. Fat accumulation in NASH is associated 
with a decrease in insulin and an increase of fat in the diet. Therefore, a decrease in 
glucose uptake and an increase in free fatty acids are seen.
The second hit is thought to be due to an increase in hepatic oxidative stress, 
which is greater than the antioxidant defenses. This leads to activation of stellate cells, 
causing fibrosis and the generation of proinflammatory cytokines. Inflammation, 
hepatocyte swelling, and ultimately death are a result of the proinflammatory cytokines. 
This perpetuates the formation of Mallory bodies and fibrosis.
As body mass index (BMI) increases, the fat in the liver increases. Over the past 
several decades, Americans have become more overweight. Notably in 2008, there was 
not a state within the country with less than 15% obesity (see Figure 2). A key 
consequence of obesity is the development of insulin resistance and the metabolic 
syndrome. This development provides a critical link between obesity and NAFLD.
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Figure 2: Obesity Trends Among U. S. Adults
Obesity Trends* Among U.S. Adults 
BRFSS, 1990, 1999, 2008
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Source: CDC Behavioral Risk Factor Surveillance System.
The prevalence of NAFLD and NASH increases among the morbidly obese. 
Normal transaminase levels do not exclude NASH or fibrosis (Mofrad, Contos et al. 
2003). Patients undergoing bariatric surgery have a prevalence o f 84-96% 
NAFLD/NASH, 25-55% progress to NASH. Further breaking down the NASH 
components , 34%-47% have fibrosis and 2% to 12% have bridging fibrosis or cirrhosis 
(Clark 2006).
Machado (2006) reanalyzed 12 observational and transversal studies involving 
1620 patients who had undergone bariatric surgery. All these 12 studies enrolled patients 
consecutively and analyzed data prospectively. The prevalence of steatosis averaged 
91% (range 85% to 98%), and the prevalence of NASH averaged 37% (range 24% to 
98%). The conditions most frequently associated with NASH were diabetes and insulin
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resistance. Hypertension was most frequently associated with advanced hepatitic 
fibrosis(Machado, Marques-Vidal et al. 2006). Post-surgery, there appeared to be a 
decrease in the grade of steatosis and in most cases a decrease in the grade of hepatic 
inflammation and stage of fibrosis (Barker, Palekar et al. 2006; de Almeida, Rocha et al. 
2006).
Steatosis
Numerous studies have found an increase in alanine aminotransferase (ALT), 
triglycerides, and body mass index (BMI) were the most sensitive markers of steatosis.
In the Dallas Heart Study (Browning, 2006), hepatic triglycerides content was 
determined by proton magnetic resonance spectroscopy (MRS) in a multiethnic cohort of 
2287 subjects. The median hepatic triglycerides content was 3.6% but it varied widely 
from 0% to 41.7% (Browning, Szczepaniak et al. 2004). Overall, nearly a third of the 
study population had hepatic steatosis, but the prevalence varied by ethnicity: among 
Hispanics the prevalence was 45%, among Caucasians 33%, and among Blacks 24% 
(Browning, Szczepaniak et al. 2004; Weston, Leyden et al. 2005). The higher prevalence 
of hepatic steatosis in the Hispanic population was related to the higher prevalence of 
insulin resistance and obesity. However, the lower prevalence of hepatic steatosis in 
Blacks was not explained by ethnic differences in BMI, insulin resistance, alcohol 
consumption, or medication use(Browning, Szczepaniak et al. 2004). The National 
Institutes of Health (NIH) are currently investigating genetic risk factors for NAFLD and 
this provides evidence of a genetic component to NAFLD.
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Metabolic Syndrome
The American Heart Association and the National Heart, Lung, and Blood 
Institute Scientific Statement (Alberti, et al, 2009; Grundy, 2005) have identified the 
metabolic syndrome as a group of interrelated metabolic risk factors. The presence of 
these factors identifies a person at risk for atherosclerotic cardiovascular disease and type 
2 diabetes mellitus. Key risk factors include abdominal obesity and insulin resistance. 
Additionally three of five o f the following risk factors constitutes a diagnosis of 
metabolic syndrome: abdominal obesity (waist circumference of >102 centimeters in men 
and >88 centimeters in women), elevated fasting glucose of > 100 mg/dL, elevated 
triglycerides of >150 mg/dL, low HDL of <40 mg/dL in men and <50 mg/dL in women, 
and hypertension, defined as a systolic pressure o f >130 mm Hg and a diastolic pressure 
of >85 mm Hg. Metabolic syndrome is associated with a variety of conditions, including 
fatty liver (Grundy, Cleeman et al. 2005).
Using the criteria o f the National Cholesterol Education Program’s Adult 
treatment Panel HI guidelines, Marchesini and others (2003) found the prevalence of 
metabolic syndrome to be 36% in 304 consecutive non-alcoholic fatty liver disease 
patients without overt diabetes. The prevalence of metabolic syndrome increased with 
increasing BMI, from 18% in normal weight individuals to 29% in overweight 
individuals to 67% in obese individuals. Metabolic syndrome was also significantly 
associated with female gender (OR =3.02; 95% Cl: 1.57 to 6.02) and age (OR = 1.54; 
95% Cl 1.23 to 1.93 for every 10 years). Eighty eight percent o f the subjects diagnosed 
with NASH by liver biopsy (120 subjects out o f 163 subjects obtaining liver biopsies) 
had metabolic syndrome. The other 43 patients had pure fatty liver disease. Clearly the
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presence of metabolic syndrome places patients at risk of NASH and further progression 
to fibrosis and cirrhosis.
Dietary and Lifestyle Habits
Dietary habits may contribute to the development of NASH. When food intake 
was reviewed in a cohort of 25 NASH patients and a healthy control matched group for 
BMI, age, and gender, the NASH patients were found to consume a diet higher in 
saturated fat and cholesterol and lower in polyunsaturated fat, fiber, and antioxidant 
vitamins C and E (Capristo, Meiele et al. 2005). In another study, NASH patients were 
found to consume a diet higher in total calories (energy) than healthy controls (Musso, 
Gambino et al. 2003). Musso (2003) also examined the relationship of dietary habits to 
insulin sensitivity and postprandial triglyceride metabolism. They found the insulin 
sensitivity index was significantly lower in NASH patients and was correlated with 
saturated fat intake and postprandial rise of triglycerides. There was also a suggestion of 
a defect in ApoB secretion since the apolopoprotein (Apo) B48 and APO B100 responses 
were flat and dissociated from the triglyceride response in NASH patients. Musso and 
colleagues concluded dietary habits may promote steatohepatitis directly by modulating 
hepatitis triglyceride accumulation and antioxidant activity, or indirectly, by affecting 
insulin sensitivity and postprandial triglyceride metabolism.
Much work has been done on the association of dietary intake and metabolic 
syndrome, but few studies have focused on dietary habits associated with NAFLD 
.Tendler et al. (2007) found in a study of five patients a low carbohydrate, ketogenic diet 
led to significant improvements in liver histology in patients with NASH/NAFLD. There
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were improvements in both steatosis and necroinflammatory grade and there was also 
reduction in the fibrosis pattern in three patients. One patient experienced histological 
worsening. However, this patient was not compliant with the diet, nor did he lose weight. 
It was difficult to determine whether histologic changes were due to a low carbohydrate 
diet to the weight loss experienced by participants. This study suggests decreased 
carbohydrate intake may have an independent beneficial effect on fatty liver.
Zelber-Sagi et al. (2007) examined the dietary habits o f 349 Israeli volunteers, 
findings indicated the NAFLD group (diagnosed by ultrasound)consumed less fish rich in 
omega-3, almost twice the amount of soft drinks and27% more meat. The higher intake 
of soft drinks and meat was associated with an increased risk o f  NAFLD, independent of 
age, gender, BMI and total calories. Studies have also shown that a fructose-enriched 
diet leads to development of macrovesicular and microvesicular fat deposits and 
increases in hepatitis triglyceride and cholesterol levels. These findings suggest high 
carbohydrate diets may contribute to NAFLD ((Ackerman, Oron-Herman et al. 2005).
Medications for NAFLD
There is no definitive pharmacotherapy for the treatment of NAFLD. This is a 
multifactoral disease in which insulin and insulin resistance plays a fundamental role. Fat 
accumulation in the liver is a consequence of lipids in the liver, adipose tissue, muscle 
and gut. Anti-oxidants in the hepatocytes are lacking, but this is thought to be due to 
increasing oxidative stress. Together these problems cause inflammation and fibrosis 
reducing the activation of Kupffer and stellate cells.
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Ongoing studies are looking at pharmacology interventions to prevent disease 
progressions. The drugs currently being used are insulin sensitizers (metformin, 
pioglitazone, and posiglitazone), antioxidants (vitamins E, C and silymarin), 
hepatoprotective agents (betaie, s-adenosyl, and ursodeoxycholic), hypolipidemic drugs 
(fibrates, statins, and omega 3 fatty acid), anti-tumor necrosis factor regimens 
(pentoxifylline and adiponectin) and angiotensin receptor blockers (losartan)
(Belfort, Harrison et al, 2006; Harrison, Torgerson et al, 2002; Neuschwander-Tetri,
Brunt et al., 2003; Promrat, Lutchman et al., 2004; Schwimmer, Middleton et al., 2005).
The thiazolidinediones class improves insulin sensitivity primarily in adipose 
tissue by activating the nuclear transcription factor-perioxisome proliferator-activated 
receptor-y (PPAR-Y) through binding ligands. Treatment with pioglitazone along with 
changes in diet has found to significantly improve hepatic insulin sensitivity and glucose 
clearance. Hepatic fat content declined by 54% after treatment for 6 months with 
pioglitazone and diet while it remained unchanged in a group treated with placebo and 
diet. Pioglitazone appears to have direct anti-fibrotic effects on the liver by preventing 
the activiation of hepatitic stellate cells, resulting in reduced expression of type 1 
procollagen, smooth muscle actic and transforming growth factor-Bl (TFG-B1) (Belfort, 
Harrison et al. 2006).
Metformin has not shown consistent results in the trials. It improves insulin 
sensitivity primarily in the liver, but histologic improvement has been generally limited 
(Bugianesi,Gentilcore et al., 2005; Goodarzi & Bryer-Ash, 2005; Loomba, Luchmann et 
al., 2006; Nair, Diehl et al., 2004).
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Combining vitamin E with pioglitazone significantly improved metabolic 
parameters and reduced steatosis, cytologic ballooning, Mallory’s hyaline bodies and 
pericellular fibrosis from baseline(Sanyal, Mofrad et al. 2004). These findings are 
promising, however they must be interested with caution due to the limited sample size.
Evaluation of the Individual for the Presence of NAFLD
A thorough history o f the individual and a physical examination begin the process 
of identifying NAFLD. NAFLD is the most common cause of asymptomatic elevated 
liver enzymes, found in 77% of patients (Cortez-Pinto & Camillo, 2004). The most 
frequent symptoms expressed by the individual are right upper quadrant pain, fatigue, and 
abdominal discomfort. The examiner may find hepatomegaly and abnormal liver tests.
A complete hepatic panel with gamma-glutamyl transferase, AST, ALT, and total 
bilirubin is needed. However, the NIH criteria differ from the laboratory values found on 
lab tests. Normal liver enzymes for a woman are ALT of 19 and for a male, 30. Results 
higher than these are considered elevated (Prati, Taioli et al. 2002). In NAFLD, ALT is 
greater than AST ((Huber 2004).
Additional laboratory tests are needed to exclude alternate causes of abnormal 
liver enzymes. A hepatitis panel to rule out viral hepatitis, and iron studies and ferritin 
to rule out hereditary diseases such as hemochromatosis are needed. A thyroid panel, 
especially thyroid stimulating hormone (TSH), needs to be checked since thyroid 
abnormalities may alter liver function. Anti-liver-kidney microsomal antibodies, 
antinuclear antibodies, and anti-smooth muscle antibodies will indicate whether 
autoimmune hepatitis is a culprit. Primary biliary cirrhosis is identified by a greater than
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1:4 positive antimitochondrial autoantibody titer. Alpha-1 antitrypsin antibodies help 
identify hereditary enzyme deficiency that leads to both lung and liver disease.
There are also noninvasive studies to identify the presence of steatosis. 
Sonography is the most commonly used method. Computerized tomography and MRI 
have also been used, though none of these are ideal. No imaging study to date has been 
able to distinguish between simple fatty liver and NASH or with fibrous NASH.
However, this area continues to be investigated for the ability to assist in the diagnosis of 
NASH.
Liver biopsy remains the “gold standard” for the definitive diagnosis of NAFLD. 
It completes the work-up in individuals without significant coagulopathy and who are at 
high risk for having bridging fibrosis based on other clinical and laboratory parameters. 
The decision to perform a biopsy continues to be debated, though a biopsy makes it 
possible to predict a patient’s clinical pathway based on the findings of the biopsy.
Simple steatosis has a low likelihood of progression to advanced liver disease. NASH is 
more likely to progress to advanced disease, with or without fibrosis. The biopsy, 
however, has potential risks related to the procedure itself and the current lack of 
treatment for NAFLD.
NAFLD: Therapeutic Approach
Based on the data, it is possible to construct a therapeutic algorithm that can be 
used to treat patients with NAFLD. Treatment of NAFLD has focused on the underlying 
metabolic risk factors. Those with overt features of metabolic syndrome (obesity, 
diabetes, hypertension and dyslipidemia) should have those diseases treated according to
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standard approaches. Regardless of whether or not patients exhibit other features of 
metabolic syndrome, all individuals with NAFLD should have some form of therapy for 
their liver disease. Fatty liver may be categorized as primary or secondary depending on 
the pathogenesis. Distinction between primary and secondary types is important since 
these have different treatment and prognosis.
Treatment is guided by the severity of the liver damage, and the degree of proof 
of therapeutic efficacy and safety. Patients with simple steatosis should be encouraged to 
reduce caloric consumption and increase physical activity, using an approach that 
improves insulin sensitivity in diabetes ( Andersen, Gluud et al. 1991; Drenick, Simmons 
et al. 1970; Rozenthal, Brava et al. 1967). Patients with steatohepatitis should be given 
similar advice and may also be encouraged to enroll in one of the several treatment trials 
underway. Patients with cirrhosis should receive standard therapy for portal hypertension 
and undergo routine screening for hepatocellular carcinoma. I f  hepatic decompensation 
ensues, patients without contraindications for surgery should be considered for orthotopic 
liver transplant (OLT).
Once NAFLD has been diagnosed, periodic monitoring to assess disease 
progression is needed. NAFLD can reoccur after liver transplant, and aggressive efforts 
are needed to prevent and treat metabolic syndrome post-OLT(Sutedja, Gow et al. 2004; 
Ghali and Lindor.2004). If diet contributes to NASH, then weight loss may help reduce 
fat deposits. In women with gestational diabetes, a weight loss of 8% was associated 




Dietary treatment to prevent and control NAFLD has not been clearly defined.
The diet for weight loss remains debatable, though a diet enriched with unsaturated fatty 
acids is theoretically reasonable. Restricting calories is known to achieve weight loss. 
Foods with a low glycemic index may reduce mean incremental blood glucose. In 
summary, lifestyle modifications incorporating a gradual weight loss and increased 
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Facilitating Lifestyle Changes to Manage Progressive Fatty Liver Disease 
Abstract:
Background: With the increase in obesity in the United States, and the rising incidence 
of metabolic syndrome, more patients are presenting with abnormal liver injury tests 
related to fatty liver. There is no standard therapy for fatty liver disease other than 
lifestyle changes to combat the metabolic derangement and avoid the progression to 
NASH/cirrhosis. The aim of this study was to describe the relationship of the intensity in 
care management by the nurse practitioner on education and support of lifestyle changes 
to improve metabolic parameters in patients with fatty liver. Methods: Seventeen 
patients were identified with a diagnosis of Fatty Liver disease-13 adult patients and 4 
pediatric patients. Patients were identified through elevated liver enzymes, and exclusion 
of all other possible liver diseases. Patients were followed every 2-3 months initially and 
then tailored to the individual patient needs resulting in 1 month to 3 month follow up. 
Each structured clinic visit lasted 30-45 minutes to assess patients and discuss lifestyle 
changes. Results: Thirteen adults-8 females (62%) and 5 males (38%), age range 29-72
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years and four pediatric subjects-3 males and 1 female, age range 12-17 years were in the 
study. The adult participants had an initial BMI of 30.93±3.7, AST 49.5±27.8, and ALT 
71.5±43.8, while the pediatric participants had a BMI of 33.33±6.3, AST of 42.3±14, and 
ALT 66.65±36.6. During the follow-up period, the adult participants self-selected to 
increase frequency of visits to monthly or every other month for self-accountability. Diet 
changes were more difficult in adults since 85% of the adult’s skipped either breakfast or 
lunch. The adult averaged 4 medications-including antihypertensives, and cholesterol 
medications. The pediatric participants continued with every 3 months but increased 
their physical exercise to 5 times a week-1-1/2 hours per session. Their diets included 
more fruits and vegetables previously lacking. By self-report, they made better choices 
through the school lunch program. The BMI remained relatively stable for 6 months for 
both groups, though at three months ALT and AST was normal in the adult group in 55% 
and 44% respectively. In contrast, 100% of the pediatric participants achieved normal 
AST and ALT levels by 3 months. Adolescent growth in height facilitated the mild 
changes in the BMI, whereas in the adult, the BMI changes were based on actual weight 
loss. Conclusions: Outside clinical trials; (1) management of fatty liver is feasible; (2) 
improvement occurs with dedicated time and a contract with the patient-listening to their 
individual needs, (3) albeit chemical and metabolic improvement occurs, it is slow, and 
(4) pediatric patients require full participation and family support in lifestyle changes of 
the patient to achieve the goals of therapy. The trial showed to be labor intensive and this 
model could be the most cost effective.
Introduction
Non-alcoholic fatty liver disease is emerging as an increasingly important cause 
of liver disease. It is associated with obesity, diabetes, and insulin resistance. Non­
alcoholic fatty liver disease (NAFLD) can lead to cirrhosis and may result in significant 
morbidity and eventual mortality. Though there is no specific therapy, exercise and 
nutritional intervention appears to improve and prevent these inter-related conditions.
The risk of progression from NAFLD to cirrhosis is 1-2% over 15 to 20 years, 
whereas the risk for progression from NASH to cirrhosis is 12-20% over 8 years (Adams, 
Lymp et al. 2005; Adams, Sanderson et al. 2005; Sanyal, Banas et al. 2006; Dam-Larsen, 
Becker et al. 2009). Additionally, there is a more rapid progression of fatty liver disease 
when obesity and diabetes confound the health issues.
The changes to the CDC-Behavioral Risk factor surveillance system, which 
provides the prevalence of self-reported obesity among United States adults have resulted 
in a new baseline. Traditionally the telephone survey was based on land lines, and this 
year cell phone users were surveyed to obtain data that better represents the diverse 
population (CDC, 2011). This expanded and improved way to gather and process 
information does not accurately compare to previous findings. More than one-third of 
United States Adults are obese. In fact there is not a state less than 20% obesity. The 
Southern States have the highest obesity rate at 29.5% (Table 6). Our clinic population in 
Southern California is primarily Hispanic/Latino and the obesity rate is around 40%.
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Table 6: Prevalence of Self-Reported Obesity Among U.S. Adults, 2011
Obesity Prevalence
Prevalence o f Self-R eported O besity  Among U.S. A dults 
BRFSS, 2011
Numerous studies have found that an increase in alanine aminotransferase (ALT), 
triglycerides, and body mass index (BMI) were the most sensitive markers of steatosis.
In the Dallas Heart Study, hepatic triglycerides content was determined by proton 
magnetic resonance spectroscopy (MRS) in a multiethnic cohort of 2287 subjects. The 
median hepatic triglycerides content was 3.6% but it varied widely from 0 to 41.7 
percent. Overall, nearly a third of the study population had hepatic steatosis, but the 
prevalence varied by ethnicity: among Hispanics/Latinos the prevalence was 45%, 
among Caucasians 33%, and among blacks 24% (Browning, Szczepaniak et al. 2004; 
Weston, Leyden et al. 2005). The higher prevalence of hepatic steatosis in the 
Hispanic/Latino population was related to the higher prevalence of insulin resistance and 
obesity. However, the lower prevalence of hepatic steatosis in Blacks was not explained 
by ethnic differences in BMI, insulin resistance, alcohol consumption, or medication use 
(Browning, Szczepaniak et al. 2004). The National Institutes o f Health (NIH) are
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currently looking into genetic risk factors for NAFLD which may provide evidence of a 
genetic component to NAFLD.
Metabolic Syndrome
The American Heart Association and the National Heart, Lung, and Blood 
Institute Scientific Statement have identified the metabolic syndrome as a group of 
interrelated metabolic risk factors. The presence of these factors identifies a person at 
risk for atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Key risk 
factors include abdominal obesity and insulin resistance. Additionally three of five o f the 
following risk factors constitutes a diagnosis of metabolic syndrome: abdominal obesity 
(waist circumference of >102 centimeters in men and >88 centimeters in women), 
elevated fasting glucose of > 100 mg/dL, elevated triglycerides o f >150 mg/dL, low HDL 
of <40 mg/dL in men and <50 mg/dL in women, and hypertension, defined as a systolic 
pressure of >130 mm Hg and a diastolic pressure of >85 mm Hg. Metabolic syndrome is 
associated with a variety of conditions, including fatty liver .
The economic impact of chronic illnesses, specifically fatty liver disease and 
obesity, is a burden to the health care system. While these diseases are often associated 
together, they are also linked with a higher risk for several other serious health conditions 
such as hypertension, type 2 diabetes, hypercholesterolemia, and coronary artery disease. 
Direct medical costs and indirect costs such as absenteeism from work, decrease 
productivity, and disabilities are increasing with the rise o f obesity and fatty liver disease. 
Baumeister et al (2008) reported an increase of 26% in health care costs of a patient
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diagnosed with fatty liver disease. There were reports the cost of obesity in 2008 to be 
estimated as high as $147 billion.
The current treatment of fatty liver disease remains diet, exercise and weight loss, 
though there is little data to support the intensity. Maintaining weight loss in clinical 
practice is difficult despite the benefits.
Aim:
The aim of this study was to describe the relationship of the intensity of care management 
on education and support lifestyle changes to improve metabolic parameters in patients 
with fatty liver disease.
Methodology
A repeated measures non experimental feasibility study design was used for this 
study. The sample was recruited from patients referred to Southern California Liver 
Centers with elevated liver enzymes. Between September 2011 and January 2012, 17 (13 
adults and 4 adolescents) patients were identified with a diagnosis of fatty liver disease. 
Inclusion criteria were elevated liver enzymes and the exclusion of all other liver disease. 
Patients were both English and Spanish speaking. The study procedures, including the 
protocols for health care and obtaining informed consent were reviewed and approved by 
the administrative and Univeristy institutional review boards.
Demographic Data:




Co-morbidities were assessed through medical record audits, diagnostic (ICD9 
codes), health care utilization (outpatient, inpatient, and emergency room encounters), 
patient history. All medication and pharmacy information was taken at each visit as 
standard procedure in the clinic. Patients were/are asked to bring in all medications to 
verify dosage and frequency. At the initial visit personal and family history are taken 
including diseases related to liver, diabetes, cancer, cardiovascular, and obesity and risk 
factors for such diseases.
Clinical Criteria:
NAFLD was diagnosed based on a combination of clinical features, blood profile, 
and radiological imaging or liver biopsy. The blood profile included evidence of elevated 
liver enzymes, gamma-glutamyl transpeptidase, and alkaline phosphate. Radiological 
features identified fatty infiltrations or fibrosis. A liver biopsy identified the percent of 
steatosis or provided a NAFLD Activity Score (NAS).
Nutritional Assessment:
Nutritional assessment was based on the following: anthropometry, 24 hour diet 
recall, and laboratory values of vitamins and minerals. All measurements were taken by 
the same investigator to avoid any inter-observer variation.
Anthropometry:
All patients had a baseline body mass index (BMI) calculated at each clinic visit. 
BMI was calculated by dividing weight in kilograms by height in meters squared and
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calculated according to the Centers for Disease Control and Prevention adults charts.
BMI was used as a baseline comparison. The waist circumference was taken at the level 
of the iliac crest, placing a tape measure in a horizontal plane (parallel to the floor) with 
participant standing. The measurement was taken at the end of expiration and snug but 
not compressing the skin. Additional anthropometric measurements include the 
following midarm circumference (MAC), triceps skin fold thickness (TST), biceps skin 
fold thickness (BST), and handgrip strength. MAC was measured midway between the 
tip of the shoulder and the tip of the elbow (olecranon process and the acromium) to the 
nearest millimeter with a measuring tape for both the right and left arm. The participants 
palm was facing the thigh. TST and BST, established measures o f fat stores, was 
measured to the nearest millimeter on both arms using the Harpenden skin fold calipers in 
a standard manner. Each measurement was taken three times and the average values 
calculated and recorded (Lee & Nieman, 2007).
Visceral proteins
Serum albumin concentration is the most frequently used laboratory measure of 
nutritional status. It has been used to assess change in nutritional status and stratifying 
the risk of malnutrition. Serum proteins are affected by capillary permeability, drugs, 
impaired liver function, and inflammation. In a dehydrated patient, albumin levels may 
be falsely high due to decrease plasma volume. Because of a relatively long half-life of 
approximately 14-20 days, albumin has been identified as a marker of chronic nutritional 
status. Albumin is expected to return to normal as the inflammatory response resolves.
Dietary intake and assessment
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The assessment of the individual patient’s intake was determined by the dietary 
recall method of the patient. The patient was instructed to write down the daily intake 
and time of intake in a provided food diary. If they did not bring this diary, the provider 
reviewed the previous 24 diet recall of the patient at the time of the visit. The objective 
was to determine the categories of food eaten based on the pyramid.
Lifestyle Changes
The changes in lifestyle were determined by self-reported modifications of diet 
and exercise. The patient set goals at each visit and reviewed at subsequent visits with 
the APRN. The goals set involved changes or modifications in diet, exercise, and sleep 
patterns.
Statistical Analysis
All data was entered into Statistical Packages for the Social Sciences (SPSS) version 16.0 
(Chicago, Illinois, USA) software for analysis. Descriptive statistics were calculated for 
all analysis variables.
Results
Seventeen patients with diagnosed fatty liver disease were identified during 
September 2011 through January 2012. There were 13 adults and 4 adolescents. The 
mean age of the adults was 58.8 ±12.9 (range 29-72 years) and the mean age of the 
adolescents was 16 years ±2.9 (range 12-17 years). The majority of patients (n=15) 
chose to respond to the assessment interviews in English. All participants had a 
diagnosis of elevated liver enzymes for referral to the specialist. Obesity was seen in 100
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% of the participants; not surprising given that obesity is a risk factor for NAFLD. The 
initial laboratory values indicated a mild to moderate increase in liver injury tests. The 
hepatic function was intact. There was no biochemical evidence o f cirrhosis. The 
laboratory results indicated non cirrhotic liver patients, without infection or anemia. The 
liver enzymes were elevated in all the adults and adolescents. The basic demographic 
and clinical features are presented in Table 7.
Table 7: Basic Demographic and Clinical Features
Demographic Data and Clinical Features  
adults n=13, adolescents n=4 unless o th erw ise  stated
m n mamm
WBC 6.4 ±1.4 6.911.4 3.8-10,8 thousand/uL
H6B 14.2511.4 13.710.73 11.7-15.5 g/dL
Pits 242.8159.6 277.75141.7 140-400 thousand/uL
ALT 71.5±43.8 66.651396.6 6-40 U/L
AST 49.5+27.8 42..3114 10-35U/L
GGT 201.51262.2 n=6 30.5126.2 n=2 0-45 U/L fem ale 
0-65 U/L male




DM 5/13 1/4 :
HTN 4/13 0 /4
CAD 0 /0 0 /0
Hyperlipidemia 6/13 1 /4
Patients were followed every 2-3 months but tailored to the individual patient 
needs and preferences. Each structured visits lasted 30-45 minutes to assess patient 
clinical condition, discuss lifestyle changes and develop and evaluate goals. At the initial 
visit, the laboratory tests include a CBC, CMP, lipid panel, fasting insulin, hemoglobin 
A1C, vitamins E, B6, K, D, and folate, and minerals Calcium, phosphorus, zinc, copper,
8 0
iron, selenium, and magnesium. At subsequent visits, laboratory values of CBC and 
CMP, and other labs as directed by patient evaluation and calculated BMI were done.
Both the adult and adolescent groups had co-morbidities. There was almost 50% 
of Diabetes type 2, hypertension, and hyperlipidemia seen in the adults. Surprisingly, 
one adolescent patient was diagnosed as pre-diabetic and borderline hyperlipidemia. At 
the time, he was not placed on medications. Diet and exercise were prescribed by his 
primary physician for treatment.
Initial anthropometric measurement of waist, arm circumference, bicep and tricep 
skin fold, and BMI were increased in both groups (Table 8). The waist measurement of 
the adults was 41.5 inches ±2.68 and the adolescent waist was 43 inches ±6.14. The mid 
arm circumference of the right side was 32.5 cm ± 1.64 for adults and 37.3 cm ± 1.43 for 
adolescents. The left mid arm circumference was 34 cm ± 1.86 and 37 cm ±1 .53, adults 
and adolescents respectively. The triceps was measured for both right and left in the 
adults and adolescents. The results were 20.5 mm±3.83 and 21.4 mm±4.65 in adults and 
29.5 mm±2.12 and 27.4 mm±6.22 in adolescents. The biceps in the adults and 
adolescents were also measured on the right and left side. The adults biceps for the right 
was 19.6mm ±5.68 and for the left was 20.17mm±4.54. The adolescent right and left 
bicep was 28 mm±9.89 and 33.5 mm±9.19, respectively.
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Range 13.8-14.2 males 
based on age 
Rang e 22.3-24.9 
females based on age
18-25
Over the six months of assessment, the adults lost weight, decreasing their body 
mass index (BMI) from 30.9 initially to 30.3 at six months. The adolescents increased 
their BMI initially at 33.3 to 35 at six months. During this time period, the height of the 
adolescent remained unchanged. At six months, 2 of the adolescents began to increase in 
height (Table 9).
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Table 9: Body Mass Index changes over 6 months in Adults and Adolescents
■  Adults 
□  A dolescents
Laboratory studies indicated both groups were non cirrhotic (Table 7). Albumin 
levels were 4.29 ±0.39 and 4.5 ±0.21 in adults and adolescents respectively. The GGT 
was initially high 20.1 ±206.2 (n=6) in the adults and 30.5 ±26.2 (n=2) in the adolescents 
Initial elevated liver enzymes of ALT 71.5 ±43.8 and 66.65 ±39.6, and AST 49.5 ±27.8 
and 42.3 ±14 in the adults and adolescents respectively were found (Table 10). At three 
months, the ALT and AST were normal in the adolescents. While in the adults, the ALT 
and AST were normal in 55% and 44% respectively.
At six months, the ALT and AST remained normal in the adolescents (Table 11). While 
in the adults, the ALT and AST continued to decrease to normal levels.
30
initial 3 m o n th s  6 m on ths
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Table 11: Liver Function Tests at 6 Months in Adults and Adolescents
■ Adults 
□ Adolescents
■  a d u l t s
AST ALT
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A healthier choice of foods over the six month period emerged. For the adults, 
diet changes were more difficult since 85% of the adults skipped either breakfast or 
lunch. There were two adults who skipped both breakfast and lunch. Initially both 
groups did not meet the required number of servings. The adults did consume the better 
diet, through poor, and the adolescents consumed higher fat content. At six months, 
though not adequate, improvement was noted in the food choices made (Table 11). The 
participants increased fruits and vegetables to an average of 6 servings in the adults and 2 
3A servings in the adolescents. Adults increased their servings o f protein, and grains, 
while decreasing their fat intake at six months. Adolescents reported an increased 
awareness of better food choices through the school lunch program. They found ways to 
improve their school lunch program by removing breading off the chicken tenders and 
adding more vegetables to the salad, a choice they had rarely done before.








Exercise was addressed at each visit. The adults found exercise to be difficult to schedule 
in their daily activities. However, they did increase their exercise times to twice a week 
for an average of 30 minutes. They stated it was hard to incorporate exercise into their 
lives as they usually exercised by themselves. The adolescents increased their physical 
exercise to 5 times a week lasting 1 to 1.5 hours per session. The family became part of 
the exercise team.
Discussion
The current study was designed to address the intensity of care management as 
evidenced by length of scheduled visits, time spent developing new goals and reviewing 
previous identified goals, needed on education and supporting of lifestyle changes to 
improve metabolic parameters in patients with fatty liver disease. In this study, the 
protocol was for visits every three months, The adults self-selected for monthly visits for 
weight checks and provider visits every 2-3 months. The adolescents chose to continue 
with every 3 month visits citing family constraints. We did not add medication to either 
group.
Each visit was/is a re-evaluation of where the participant has been and where they 
are headed in their changes of lifestyle. Goals are evaluated, modified, and created with 
the participant. Listening to your patient, becoming an advocate and cheerleader for their 
successes and celebrating the successes-small or big, help the patient. The goal is a 
healthy lifestyle-it takes work and commitment.
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Though most clinical trials have used a balanced diet with restriction, we focused 
on the food pyramid and healthy choices of complex carbohydrates and a decrease of fats 
in the diet. Adults increased their servings of fruits and vegetables, proteins, and grains. 
Though the adolescents presented with a higher BMI, the adults presented with higher 
ALT and AST.
A major finding in this study was that frequency and time allocated of visits and 
mutual goal setting improved the outcome of the liver enzymes. Outside of clinical trials, 
management of fatty liver is feasible, but intense. Improvement occurs with dedicated 
time and a contract with the patient, listening to the patient, allows for tailoring the 
program albeit, chemical and metabolic improvement is slows, it does occur. 
Modifications of diet and increased exercise were aimed to promote weight loss.
Lifestyle changes were initiated and discussed. Adolescents require full participation and 
family support in lifestyle changes o f the patient to achieve the goals of therapy. One 
adolescent stated it gave her time with her mother to talk on their daily walks.
Though our results our similar to the literature suggesting a lifestyle change is 
needed to manage fatty liver disease, this study of a small sample size, provide additional 
data supporting the need for intensive dedicated time to the patient. It supports the need 
for the patient to be part of the structuring of their lifestyle changes. Education and 
listening to the patient becomes a key component to each visit. The guidelines for dietary 




Fatty Liver Disease is a difficult disease to treat. The United States culture 
provides an environment of high-calorie food, “super-sized” portions, and busy daily 
routines that seem to preclude time for exercise. As the risk of this chronic liver disease 
becomes more common, insulin resistance, type II diabetes, and cardiovascular disease 
increases. Though pharmacologic intervention continues to be explored, there remains 
no consensus for the use of any single drug or combination of drugs for the treatment of 
fatty liver disease.
Uneo, Sugawara and Sujaku (1997) found a three month restrictive diet and 
exercise program led to a decrease in liver enzymes, improved cholesterol and blood 
glucose levels in patients with NAFLD. St. George et al. (2009) reported increased 
physical activity reduced aminotransferase levels and weight loss in a three month study.
The literature describes a 5-8% weight loss is needed to improve liver function 
tests. Yet, in this small study, the adolescents did not demonstrate weight loss, yet 
improved liver function tests at three months. Not every patient with fatty liver disease 
requires aggressive therapy, but every patient should be started on a healthy diet and 
regular exercise program. Practical considerations for follow up is scheduling a longer 
clinic visit and listening to your patients. It is labor intensive, it could be cost effective 
for the patient, and the APRN can run this clinic.
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A Descriptive Study of Nutritional Parameters in End-Stage Liver Disease 
Abstract:
Nutrition is one of the most important factors which can influence overall 
mortality and morbidity. It is well documented, liver cirrhosis, end-stage liver disease 
(ESLD), drives a patient to a catabolic state thus depleting them of essential nutrients. 
With the standard parameters o f nutritional assessment often invalid in ESLD, it becomes 
difficult to identify and assess nutritional status. Simple and easy methods are needed to 
identify the patients approaching the state of malnutrition.
The purpose of this study was to (1) identify the incidence of malnutrition in 
patients with compensated liver disease utilizing defined nutritional parameters 
(anthropometric measurements, hand grip strength, and laboratory values) and (2) 
examine the degree of malnutrition patients with end stage liver disease secondary to 
viral hepatitis, metabolic (non alcoholic steatohepatitis) and alcoholic liver disease.
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The results of this study provide a description of nutritional parameters of 
cirrhosis based on the etiologies of Hepatitis C virus (n=15), Non-Alcoholic 
Steatohepatitis (n=9), and Alcoholic Liver Disease (n=9). Thirty three (33) subjects were
included in this retrospective study. The disease severity was Child A-14 and Child B- 
11. Diabetes type II and hypertension were the most common comorbitities. The BMI 
average across the groups was 31. Clinical assessment shows a trend toward increase in 
malnutrition. Identification of the earlier stages of malnutrition is challenging, it develops 
insidiously and maybe masked by edema, however this information is critical for 
intervention to prevent further complications in the progression o f liver disease.
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Introduction:
The liver plays a fundamental role in our body and influences the nutritional 
status. When a liver injury occurs, malnutrition may be exacerbated. Malnutrition has 
been reported as high as 90% depending on the patient population studied and the disease 
severity (Italian Multicentre Cooperative Project, 1994). Protein energy malnutrition is a 
frequent finding in patients with liver cirrhosis, and malnutrition represents a risk factor 
influencing both short term and long term survival (Campillo, Richardet, Scherman, & 
Bories, 2003; Matos, Porayko, Fransisco-Ziller, & DiCecco, 2002; & Roongisuthipong, 
Sobbonliduk, Nantiny, & Songchitsomboon, 2001). In the cirrhotic patient, lean patients 
with a Body Mass Index (BMI) of less than 18 .5 kg/m2 has been associated with protein 
energy malnutrition (PEM), though obese patients with a greater than 25 kg/m2 has a 
higher prevalence and increases the risk for hepatocellular cancer (Callee, Rodriguez, 
Walker-Thurmond, & Thun, 2003; Inoue, Iwasaki, Otani, Sasazuki, Noda, Tsugane,. 
2006; Muto, Watanabe, Moriwaki, Suzuki, Kato, Kato, M., Nakamura, Higuchi, 
Nishiguchi, Kumada, Ohashi, 2006; Yoshiji, Noguchi, Kitade, Ikenaka, Namisaki, 
Yoshii, Yanase, Yamazaki, Tsujimoto, Akahane, Kawaratani, Uemura, & Fukui, 2009).
Due to the multiple causes of cirrhosis, there are a variety of dietary habits from 
PEM to over nourishment. However, most of these studies regarding nutritional intake 
have focused on hospitalized patients ( Muto et al, 2006; Albertino, Gatta, Amodio, 
Merkel, DiPascoli, Boffo, & Caregaro, 2001; Italian Multi center Cooperative Project on 
Nutrition in Liver Cirrhosis, 1994). Though not fully understood, there are multifactorial
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mechanisms contributing to malnutrition in cirrhosis: poor dietary intake, malabsorption, 
increased protein losses in the intestine, low protein synthesis, hypermetabolism, and 
disturbances in substrate utilization. (The diet often recommended is low sodium to 
control the peripheral edema and ascites. Food may become unpalatable leading to 
decrease in intake. A low zinc or magnesium level can distort or decrease taste sensation 
(Madden, Bradbury, & Morgan, 1997; &Yang, Lai, Chiang, Chen, & Chen, 2004).
Poor nutritional status is the single reversible prognostic marker in cirrhosis. 
Multiple studies have suggested a causal relationship between malnutrition and survival 
(Alberino et al, 2001; Norman, Kirchner, Lochs, & Pirlich, 2006). Notably, malnutrition 
has been associated with impaired immunity and increased susceptibility to infections.
There is currently is no gold standard for clinical assessment. Body weight is 
influenced by ascites and peripheral edema in the patient with liver disease, though it was 
validated in one study (Campillo Richardet, & Boris, 2006). Nitrogen balance has been 
associated with improved outcome during critical illness, but rarely measured outside 
clinical trials (McGhee, Henderson, & Millikan, 1983). Plasma protein and 
anthropometry are common bedside assessments but have significant drawbacks.
The purpose of this study was to identify the incidence o f malnutrition in patients 
with compensated liver disease utilizing defined nutritional parameters (anthropometric 
measurements, hand grip strength, and laboratory values) and examine the degree of 
malnutrition patients with end stage liver disease secondary to viral hepatitis, metabolic 
(NASH) and alcoholic liver disease.
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Methods:
A retrospective study was conducted to identify malnutrition in outpatients with 
liver cirrhosis and to compare the differences in the nutritional status of the patients with 
NASH, HCV, alcohol, and combinations of diseases using a variety of objective 
measures including clinical examinations, anthropometric measurements and dietary 
intake. One hundred five charts were reviewed and the sample included thirty three 
subjects meeting the criteria of diagnosis cirrhosis, nutritional data available and not 
currently in a clinical trial. Secondary data analysis was conducted on data abstracted 
from the medical record of patients receiving services from Southern California Liver and 
GI Centers in San Diego and Orange Counties. The Institutional Review Board of the 
University of San Diego approved the study protocol and Southern California Liver and 
GI Center agreed to allow the review of patient’s chart. The data collected was routine 
clinical procedure for the clinic.
Nutritional Assessment
The nutritional assessment was conducted through 24 hour patient recall. For 
each patient the following data were included: anthropometric measurements, evaluation 
of diet through food on my plate, and laboratory tests.
Anthropometric measurements
Each patient was weighed on a balance beam scale. Height was taken standing in 
bare feet with a stadiometer. Body mass index was computed as body weight (kg)/height 
(m2). Mid-arm circumference was measured at the midpoint between the tip of the 
acromion and the olecranon process using a flexible tape measure. The arm was relaxed
with the palm of the hand facing forward. The vertical pinch was parallel to the long axis 
of the arm. Skin fold measurements were determined at tricpes and biceps areas (mm), 
according to standardized protocol. All the measurements were taken using Harpender 
skin fold calipers with a pressure of 10g/mm3 applied to the surface area. The same 
operator completed the readings to reduce measurement errors. Triceps skin fold 
thickness and mid arm circumference can be measured and is used in patients with 
advanced liver disease. These anthropometric measurements are only mildly affected by 
fluid retention (Matos, Porayko,Francisco-Ziller, & Di Cecco, 2002). Muscle strength 
was measured using a dyanometer. This is a hand held device designed to measure 
muscle strength in a simple way. The participant was in a standing position with arms at 
sides without touching their body. The elbow was slightly bent. The test was 
administered on the non dominant hand. The participant squeezed the dynamometer with 
as much force as possible, being careful to squeeze it only once. This was done 3 times 
with a pause of 10-20 seconds between to avoid the affects of muscle fatigue. The results 
were recorded to the nearest pound or kilogram.
Dietary Intake
Twenty-four hour recall was evaluated through dietary interviews with the
patient.
Laboratory values
Laboratory values were measured by established laboratory methods. The 
laboratory examination included alanine aminotransferase (ALT), aspartae 
aminotransferase(AST), gamma-glutamyl transferase (GGT), alkaline phosphatase, total
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bilirubin, total, HDL and LDL cholesterol, triglyceride, hemoglobin, hematocrit, glucose, 
insulin, serum ferritin, thyroid stimulating hormone (TSH), Prothrombin time (PTT), PT, 
ENR, platelets, magnesium, uric acid, hgbAlC, vitamin d, vitamin a, and vitamin e.
Severity of Cirrhosis
Both the Child-Pugh (Child & Turcotte, 1964) and the MELD (Kamath, Wiesner, 
Malinchoc, 2001) scores were used to classify the severity of cirrhosis. The Child-Pugh 
score and he MELD score was derived from laboratory parameters.
Analysis:
Descriptive statistics were calculated for all analysis variables. Chi-square tests 
for categorical variables and one-way anova for continuous variables were used to 
examine bivariate relationships. Comparisons of measured values among the Child-Pugh 
classifications-Grade A, B, And C and etiology of cirrhosis were performed using one­
way anova, SchifFe Post hoc..
Results:
The sample was comprised of 33 patients with diagnosed cirrhosis of the liver (17 
men, mean age 56.4±9.4 and 19 woman, mean age 56.8±12.2) undergoing follow up 
between June 2012 to March 2013. Liver cirrhosis was diagnosed by clinical and 
laboratory profiles. All the subjects had liver biopsies or ultrasounds to confirm 
cirrhosis. The etiology of cirrhosis was Hepatitis C virus (n-15), non-alcoholic steato­
hepatitis (NASH) (n=9), alcohol (n=9), and a combination of liver diseases (n=3). The 
disease severity was categorized by Child-Pugh classification revealing Score A in 14
cases and Score B in 11 cases. The subjects have an average of 2.7 co-morbidities 
ranging from 0-4. The most frequently seen co-morbidities were diabetes mellitus and a 
history of hypertension. Ten percent of the subjects were taking 1-3 kinds of prescribed 
medication and 90% were taking 4 or more medications. The demographic data and 
clinical profile of the patients is presented in Table 13 and 14.
Table 13: Demographic Data of Participants.
Hepatitis C NASH Alcohol HCV/NASH Alcohol/HCV
N= 15 9 9 2 1











































8.3±2.4 5±2.8 8.8±2.3 10 0
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,95±.69 ,96±.94 1.16±.87 1.1±1.06 1.8
INR 0.9-1.1 
sec
1.9±2.7 1.2±.33 1.2±. 12 1.15±.21 1.3
Albumin 3.6-5.12
g/dL








1.27±.52 ,79±.31 ,75±.2 ,75±.21 .83
Sodium 135-146
mmol/L
137.4±3.7 139.7±1.8 134±3.5 138.5±3.5 139
Potassium 3.5-5.3 
mmol/L
4.1±.72 4.1±,26 3.9±.48 3.9±. 14 3.7
The nutritional parameters were identified by triceps skin fold thickness and hand 
grip of the non-dominant hand, waist circumference, albumin, total protein, and my plate 
categories of fruits, vegetables, protein, dairy, and empty calories, identified the subjects 
with HCV with a higher waist circumference (43.0 inches±8.5) than the subjects with 
NASH (35.17 inches±23.85) and subjects with alcohol as etiology of cirrhosis 
(32.01±19.91). Tricep skin fold thickness, was decreased in all etiologies as was hand
grip strength, five to 10 percent in the participants with each etiology. The subjects with 
NASH cirrhosis consumed more fruits, average 1.33 than either the HCV subjects or 
alcohol subjects, 0.77 and 0.5 respectively. Vegetables and Protein, albeit low, was 
consistent across groups ranging from 1.3 to 1.75 and 1.75 to 2.2 respectively. 
Differences were shown in dairy with the HCV subjects consuming at least one dairy 
product a day and the alcohol subjects consuming less than a quarter of a dairy product 
daily. Interesting tp note, two of the subjects with alcohol cirrhosis continue to drink 
actively. Alcohol intake was not noted in any of the other subjects or groups (see table 
15and 16for details).
Table 15: Nutrition Intake of Patients According to Etiology.
Normal values HCV NASH Alcohol
Fruits 1 Vz -2 cups 
daily
.77±.83 1.33±1.03 ,5±1.0
vegetables 2-3 cups daily 1.6±1.0 1.3±1.0 1.75±.957
protein 46-56 grams 
daily
2.2±1.39 2.0±.63 1.75±.5
Dairy 3 cups daily 1.0±1.41 ,66±.81 ,25±.5








































Total Protein 6.2-8.3 
g/dL
7.2±.86 6.9±.37 6.87±.46
A one way anova between groups of analysis of variance was conducted to 
explore the impact of Child Pugh scores on selected laboratory parameters-albumin, total 
bili, alanine transfemase, prothrombin time, and anthropometric measurements of body 
mass index and etiology. As expected, significance at 0.3, 0.32, and 0.001, respectively, 
the higher the body mass index, the lower the albumin and the higher the total bili, the 
higher the Child Pugh score, indicating the subject was worsening. Once cirrhotic, 
etiology made no difference (see table 17).
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Albumin 3.6-5.1 g/dL 3.985 .031
Total Bilirubin 0.2-1.2 
mg/dL
8.864 0.001
ALT 6-40 U/L 1.232 .309
Prothrombin
time
9.0-11.5 sec .540 .590
A one-way anova between groups analysis of variance was conducted to explore 
the impact of disease etiology on nutritional intake, as measured by a 24 hour nutritional 
recall and laboratory values of albumin, INR, and total protein. Subjects were divided 
into 3 groups according to the etiology of cirrhosis- Group 1-HCV, Group 2-NASH, and 
Group 3-alcoholic cirrhosis. There was no statistical significance (see table 18).
Table 18: Comparisons of selected nutritional parameters with Etiology of HCV, NASH, 
and Alcohol
Normal Values F P
Albumin 3.6-5.1 g/dL 1.251 .312
INR 0.9-1.1 sec .354 .787
Grains 5-10 servings daily 2.086 .145
Veg 2-3 cups daily .362 .782
Fruits 1 Vi-2 cups daily 1.022 .409
Oils 15 percent of 
calories consumed
8.533 .001
Protein 46-56 grams daily .494 .692
Dairy 3 cups daily .556 .653
Empty calories 120-260depending 
on gender
.784 .479
Skips breakfast 0 6.870 .003
Skips lunch 0 2.831 0.071
Skips dinner 0 .241 .867
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Discussion:
Identifying the earlier stages of malnutrition is challenging. It develops 
insidiously and maybe masked by edema. The earlier the diagnosis of malnutrition, the 
earlier interventions can be started. It has been well documented complications of liver 
disease increases with malnutrition (Cabre &Gassull, 1998). The nutritional status of 
patients with liver cirrhosis has shown great diversity and there is no gold standard for 
early diagnosis. Some have identified protein energy malnutrition and others have 
excessive nutrition and obesity. Evaluating the nutrition from the perspective of 
management of the underlying cause of cirrhosis may prevent additional liver injury. This 
study categorized subjects with cirrhosis according to the top three disease entities of 
cirrhosis. Laboratory evaluations, anthropometric measurements, 24 hour diet recall, 
etiology of cirrhosis, ascites, edema, anasarca and Child Pugh score was completed on 33 
patients.
Anthropometric measurements and handgrip strength have correlated well with 
the dual-energy x-ray absorptiometry (DEXA) (Alvares-da-Silva, & Reverbel, 2005; 
Figueriredi, Dickson, & Pasha, 2000; & Flore, Merli, & Andreoli, 1999). NASH 
subjects had a higher handgrip strength than either the HCV or alcohol subjects. Alvares- 
da-Silva and colleagues (2005) found handgrip strength as an easy and effective tool in 
assessing nutritional risk in patients with end stage liver disease. When taken serially, it 
may become very useful in clinical practice. In this study the tricep skin fold thickness 
and the hand grip strength of the non-dominant hand was decreased in all etiologies 
indicating decrease muscle tone and strength. Serially measurements need to be taken to 
validate the findings. One is cautioned the overuse of handgrip strength may
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overestimate the prevalence of malnutrition. The BMI was found to be higher in the 
subjects with HCV, but all three groups averaged BMI of 31.13±8.57. As expected, the 
NASH subjects had the highest BMI at 33.91±6.1 and the lowest BMI was the subjects of 
alcoholic cirrhosis with a BMI of 29.1±7.1. Ascites and peripheral edema was minimally 
reported in this population of subjects.
Early identified poor diets may offer opportunities for nutritional counseling. In 
this study, the subjects were not taking adequate nutrients. Consistently the subjects who 
consumed fewer fruits, vegetables, protein, and dairy had an increase in empty calories. 
Meals were skipped-breakfast the most common meal skipped. Previous research has 
shown in healthy adults; breakfast is the most important meal of the day, setting the tone 
for activity, wellness, and energy.
Muscle wasting and easy fatigability is well recognized in cirrhosis. Exercise is 
relevant as the impact of physical fitness can be improved. However, in this study, the 
subjects overall did very little exercise, citing fatigue and lack of energy as the source of 
limited exercise. Discussion of exercise was documented in the patient’s record and 
encouragement of walking was encouraged.
Clinical Assessment demonstrates a trend towards more malnourishment with 
increasing clinical severity. A larger study sample is required to support these findings. 
The goals of nutrition are to replenish malnourished individuals, maintain adequate 
muscle and energy reserve, and manage patient’s symptoms to maximize quality of life. 
With the standard parameter of nutritional assessment often invalid in end-stage liver 
disease, it becomes difficult to identify and assess nutritional status.
The results of this study must be interpreted in the context of limitations including 
a cross sectional design, a small sample, and nutritional parameters documented in the 
clinical chart. This data could form a baseline for future prospective studies and change 
the practicing standards of operating practice in clinical practice. As there is no 
longitudinal data available, continued analysis of nutritional parameters is warranted on 
an outpatient status of persons with end-stage liver disease.
Conclusions:
Cirrhosis is considered a risk for malnutrition, but needs to be looked through the 
lenses of etiology. Obesity may change the revision of nutritional standards (Shiraki, 
Nishiguchi, Saito, Fukuzama, Mizieta, Kaibori, Hanai, Nishimura, Shimizu, Tsurumi, & 
Moriwaki, 2003). Nutritional support may improve clinical outcomes in those with early 
cirrhosis. Preventing further nutrient and muscle depletion, correcting vitamin and 
mineral deficiencies may minimize the risk of infection, debility, and deconditioning 
(Campos, Matias, Coelho, 2003). Additional studies are needed to provide information 
and nutritional therapies for patients with liver cirrhosis. Nutritional education is 
important and recommended for patients with liver cirrhosis to help them in the balance 
and selection of foods with protein and nutrients.
This study continues to collect data identifying the nutritional parameters of the 
patient with cirrhosis of the liver. This data is part of a longitudinal study looking at the 
parameters of nutrition in the patient with end stage liver disease.
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PROPOSED PLAN OF RESEARCH 
My dissertation has only touched the surface of my projected research plan. There are many
threads to pursue.
1. What is the relationship between hospital visits, ED visits, physician visits, quality of life 
and outcome of the patient with fatty liver disease and end stage liver disease.
2. What is the impact of disease state on the lifestyle changes over time?
3. How do we improve strategies to assess the liver patient? What is the dry weight versus 
the wet weight (having edema and ascites)?
4. Is a change in chemical injury tests and/or BMI a predictor of liver disease regression or 
progression?
5. What are the characteristics of malnutrition with respect to etiology of cirrhosis?
This process of learning about research, a novice understanding of research and statistics, has 
only increased my thirst of finding questions. The patients are the winners in this thirst for 
knowledge. It is their experiences, their laboratory values, their anthropometric measurements, 
which when collected and analyzed will help shape the knowledge known and only lad to more 
questions.
